

# *Calendar Year 2023 Supplemental Rebate Agreement Report*

---

*February 1, 2025*



*Division of Health Care Financing and Policy  
Nevada Medicaid  
Nevada Department of Health and Human Services*

Joe Lombardo  
*Governor*

Richard Whitley, MS  
*Director*  
*Department of Health and Human Services*

Stacie Weeks, JD, MPH  
*Administrator*  
*Division of Health Care Financing and Policy*

## Calendar Year 2023 Supplemental Rebate Agreement Report Summary

Section 8 of Nevada Revised Statutes (NRS) 422.4025 requires reporting concerning the agreements negotiated and contracts entered into pursuant to NRS 422.4053 which must include, without limitation, the financial effects of obtaining prescription drugs through those agreements and contracts, in total and aggregated separately for agreements negotiated by the Department, contracts with a pharmacy benefit manager, contracts with a health maintenance organization and contracts with public and private entities from this State, the District of Columbia and other states and territories of the United States.

In Nevada, four Managed Care Organizations (MCOs) and/or their pharmacy benefit managers enter into rebate agreements and contracts to purchase prescription drugs included on the list of preferred prescription drugs for health plans under the Medicaid program. A pharmacy benefit manager enters into rebate and cost pool agreements on behalf of the Fee-for-Service Medicaid program. A summary of these agreements is provided in Table 1 below.

**Table 1**

<b>Summary of Supplemental Rebate Agreements for Health Plans – Calendar Year 2023</b>			
<b>Health Plan</b>	<b>Number of Unique Manufacturers Under Contract</b>	<b>Total Supplemental Rebates Invoiced</b>	<b>Total Supplemental Rebates Collected</b>
Anthem	182	\$6,727,984.60	\$6,494,966.52
Health Plan of Nevada	47	\$9,814,275.57	\$9,620,335.90
Molina	182	\$2,063,507.30	\$1,899,046.80
SilverSummit Healthplan	182	\$1,716,091	\$1,879,509.82
<b>Totals for Managed Care Health Plans</b>	<b>593</b>	<b>\$20,321,858.47</b>	<b>\$19,893,859.04</b>
Fee-for-Service Medicaid	50	\$17,704,580.82	\$17,846,037.74
<b>Total</b>	<b>643</b>	<b>\$38,026,439.29</b>	<b>\$37,739,896.78</b>

Each MCO has provided additional information specific to their health plan’s supplemental rebate in the attachments to this report:

- A. Anthem Blue Cross and Blue Shield Health Care Solutions
- B. Health Plan of Nevada
- C. Molina Healthcare
- D. SilverSummit Healthplan

Information in Table 3 has been masked. Additional information specific to supplemental rebate agreements related to prescription drugs for fee-for-service Medicaid recipients is provided by a pharmacy benefit manager vendor, Prime Therapeutics, LLC in Attachment E.

Enclosures:

- Attachment A – Anthem Blue Cross and Blue Shield Health Care Solutions
- Attachment B – Health Plan of Nevada
- Attachment C – Molina Healthcare
- Attachment D – SilverSummit Healthplan
- Attachment E – Nevada Medicaid Fee-For Se-Service

# **ATTACHMENT A**

## **Anthem Blue Cross and Blue Shield Health Care Solutions**

**Anthem Blue Cross and Blue Shield Healthcare Solutions**  
**Supplemental Rebate Agreement Report**  
**Calendar Year 2023**

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid Drug Rebate Program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal Unit Rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter into separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists (PDL).

Generally, the SRAs are in effect for one calendar year beginning on January 1<sup>st</sup> and terminating on December 31<sup>st</sup>. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new National Drug Codes released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31<sup>st</sup> end date such as a product moving to non-preferred status or to coincide with planned coverage review.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- "Percentage of WAC" - set percentage of the drug's published wholesale acquisition cost (WAC).
- "GNUP" (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
  - In the event a drug's WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
  - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Anthem Blue Cross and Blue Shield Healthcare Solutions price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer's SRA with the managed care organization.

Anthem Blue Cross and Blue Shield Healthcare Solutions had 218 SRAs in place that were in effect during Calendar Year 2023 (January 1, 2023 – December 31, 2023) (hereinafter referred to as CY 2023). Table 1 below summarizes the agreements. There were 218 total contracts but only 182 total manufacturers. Certain drug manufacturers had more than one contract with Anthem Blue Cross and Blue Shield Healthcare Solutions during this time.

**Table 1 Row Definitions:**

- Number of Contracts - The count of signed SRAs that were in force during some period within CY 2023.
- Number of Unique Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within CY 2023.
- Amount Plan Paid for Products During Contract Term - The amount Anthem Blue Cross and Blue Shield Healthcare Solutions paid for all drug utilization subject to a manufacturer’s SRA during CY 2023.
  - Example: Drug “A” was subject to an SRA from 04/01/2023 to 12/31/2023 would include the amount paid for Drug “A” for claims paid from 04/01/2023 to 12/31/2023.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract – The amount Anthem Blue Cross and Blue Shield Healthcare Solutions paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2023.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2023 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2023 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.
  - Example: Manufacturer B was invoiced \$100.00 for supplemental rebates in November 2022 and remitted payment in January 2023. This column would include the payment since it was made during CY 2023.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products - The result of dividing Total Supplemental Rebates Invoiced by Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term.

**Table 1**

Summary of Supplemental Rebate Agreements during CY 2023	
<b>Number of Contracts</b>	218
<b>Number of Unique Manufacturers Under Contract</b>	182
<b>Amount Plan Paid for Products During Contract Term</b>	\$136,099,012.91
<b>Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term</b>	\$136,099,063.83
<b>Total Supplemental Rebates Invoiced</b>	\$6,727,984.60
<b>Total Supplemental Rebates Collected</b>	\$6,494,966.52
<b>Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products</b>	4.94%

Table 2 below lists the SRAs in place during CY 2023. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity Anthem Blue Cross and Blue Shield Healthcare Solutions has contracted with in the SRA.
- Effective Date - The start date of the SRA.
- Term Date - The end date of the SRA.

**Table 2**

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
ABBOTT DIABETES CARE	1/1/2020	12/31/9999
ABBVIE INC	12/1/2020	12/31/9999
ACORDA THERAPEUTICS INC	1/1/2020	12/31/9999
AERIE	1/1/2020	12/31/9999
AKARX INC	9/1/2020	12/31/9999
AKEBIA THERAPEUTICS INC	1/1/2022	12/31/9999
AKORN, INC	1/1/2020	12/31/9999
ALCON LABORATORIES	1/1/2022	12/31/9999
ALEXION PHARMACEUTICALS INC	1/1/2020	12/31/9999
ALFASIGMA USA	1/1/2020	12/31/9999
ALK ABELLO INC	1/1/2020	12/31/9999
ALKERMES INC	4/1/2020	12/31/2025
ALLERGAN PHARM	4/1/2020	8/31/2025
ALMATICA	10/1/2020	12/31/9999
ALMIRALL LLC	1/1/2020	12/31/9999
ALVOGEN INC	7/1/2021	12/31/9999
AMAG PHARMACEUTICALS, INC	1/1/2020	12/31/9999
AMARIN	1/1/2020	12/31/9999
AMGEN	1/1/2023	12/31/9999
AMNEAL PHARMACEUTICALS LLC	1/1/2020	12/31/9999
ANI PHARMACEUTICALS	7/1/2021	12/31/9999
ANTARES PHARMA INC	1/1/2020	12/31/9999
ARBOR	1/1/2020	12/31/9999
ARKRAY USA INC	1/1/2020	12/31/9999
ASCEND THERAPEUTICS US, LLC	1/1/2020	3/31/2025
ASCENDIS PHARMA ENDOCRINOLOGY	11/1/2021	12/31/9999
ASCENSIA DIABETES CARE US INC	1/1/2020	12/31/9999
ASEGUA	1/1/2020	12/31/9999

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
ASSERTIO	1/1/2020	12/31/2023
ASTELLAS PHARMA US	1/1/2023	12/31/9999
ASTRAZENECA	4/1/2020	12/31/9999
AVANIR PHARMACEUTICALS	1/1/2020	12/31/2024
AVION PHARMACEUTICALS	1/1/2020	12/31/9999
BANNER LIFE SCIENCES	10/1/2020	12/31/9999
BAUSCH & LOMB	10/1/2021	12/31/9999
BAUSCH HEALTH US LLC	1/1/2020	12/31/9999
BAYER	1/1/2020	12/31/9999
BIODELIVERY SCIENCES INT	7/1/2019	12/31/9999
BIOFRONTERA INC	1/1/2020	2/28/2026
BIOGEN	1/1/2020	12/31/9999
BIOHAVEN PHARMACEUTICALS	1/1/2023	12/31/9999
BIOVENTUS LLC	1/1/2020	12/31/9999
BOEHRINGER INGELHEIM	4/1/2020	12/31/9999
BRISTOL-MYERS SQUIBB	4/1/2020	12/31/9999
CATALYST PHARMACEUTICALS	9/1/2023	12/31/9999
CEQR CORPORATION	1/1/2021	12/31/9999
CHIESI USA	1/1/2020	12/31/9999
CLARUS THERAPEUTICS	7/1/2021	12/31/9999
CLOVIS ONCOLOGY INC	1/1/2020	12/31/2023
COHERUS BIOSCIENCES	1/1/2020	8/31/2023
COLLEGIUM PHARMACEUTICALS	7/1/2019	12/31/9999
CORIUM LLC	7/1/2022	12/31/9999
COVIS PHARMA	7/1/2020	12/31/9999
CSL BEHRING LLC	4/1/2020	12/31/9999
CUMBERLAND PHARMACEUTICALS	1/1/2020	12/31/9999
CURRAX PHARMACEUTICALS LLC	1/1/2020	12/31/9999
CYCLE PHARMACEUTICALS	1/1/2020	12/31/9999
DEXCOM	1/1/2020	12/31/9999
DIGESTIVE CARE	1/1/2020	12/31/9999
DUCHESNAY USA, INC	1/1/2020	12/31/9999
EISAI INC	1/1/2020	12/31/9999
ELI LILLY & COMPANY	5/1/2020	12/31/2025
EMBECTA CORP	1/1/2020	12/31/9999
EMD SERONO	1/1/2022	12/31/2026
EMERGENT DEVICES	1/1/2021	12/31/9999
EMMAUS MEDICAL INC	1/1/2023	12/31/9999
ENDO PHARMACEUTICAL SOLUTIONS	7/1/2021	12/31/9999
EPI HEALTH LLC	1/1/2021	1/31/2024

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
ESPERION THERAPEUTICS	4/1/2020	12/31/2025
EXELIXIS INC	1/1/2020	12/31/9999
EXELTIS USA DERMATOLOGY	1/1/2020	12/31/9999
EYEVANCE	1/1/2020	12/31/2024
FERRING	1/1/2020	12/31/9999
FIDIA PHARMA USA INC	1/1/2020	8/31/2024
FRESENIUS KABI	7/1/2021	12/31/9999
FRESENIUS USA	1/1/2020	12/31/2024
GALDERMA	1/1/2021	12/31/9999
GENENTECH	1/1/2020	12/31/2025
GILEAD SCIENCES INC	7/1/2020	12/31/9999
GREENWICH BIOSCIENCES	1/1/2020	12/31/9999
GREER LABORATORIES, INC	1/1/2020	8/31/2026
GRIFOLS USA, LLC	1/1/2020	12/31/9999
H2 PHARMA	10/1/2023	12/31/9999
HARROW EYE	7/1/2023	12/31/9999
HEMA BIOLOGICS	1/1/2022	12/31/9999
HIKMA AMERICAS	1/1/2020	12/31/9999
HIKMA PHARMACEUTICALS	2/1/2023	12/31/9999
HORIZON MEDICINES LLC	1/1/2020	12/31/9999
HTL-STREFA	4/1/2021	12/31/9999
IMPEL PHARMACEUTICALS	10/1/2021	12/31/9999
INDIVIOR INC	7/1/2019	12/31/2024
INSULET	1/1/2020	12/31/9999
INTUITY MEDICAL	10/1/2021	12/31/9999
IPSEN BIOPHARMACEUTICALS INC	1/1/2020	12/31/9999
IRONSHORE	1/1/2020	12/31/9999
JAZZ	4/1/2020	12/31/2025
JOHNSON and JOHNSON	1/1/2023	12/31/9999
JOURNEY MEDICAL	9/1/2020	12/31/9999
KALA PHARMACEUTICALS INC	1/1/2020	12/31/2023
KALEO, INC	1/1/2022	12/31/9999
KOWA PHARMACEUTICALS	1/1/2022	12/31/9999
KYOWA KIRIN	1/1/2020	12/31/9999
LEO PHARMA, INC	1/1/2020	12/31/9999
LIFESCAN	1/1/2020	12/31/2025
LUPIN PHARMACEUTICALS, INC	7/1/2021	12/31/9999
MALLINCKRODT	10/1/2019	12/31/9999
MANNKIND CORPORATION	1/1/2020	12/31/9999
MAYNE PHARMA	1/1/2020	12/31/9999



Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
MEDEXUS PHARMA	1/1/2020	12/31/2023
MEDUNIK USA	7/1/2022	12/31/9999
MELINTA THERAPEUTICS LLC	1/1/2020	12/31/9999
MERCK & CO, INC	10/1/2021	12/31/9999
METUCHEN	1/1/2020	12/31/9999
MILLENNIUM PHARMACEUTICALS	1/1/2021	12/31/9999
MILLICENT	1/1/2020	12/31/9999
MINIMED DISTRIBUTION CORP	1/1/2020	12/31/9999
MISSION	1/1/2020	12/31/9999
MYLAN PHARMACEUTICALS INC	4/1/2020	12/31/9999
MYOVANT	6/1/2022	12/31/9999
NABRIVA	1/1/2020	12/31/9999
NEOS THERAPEUTICS LP	1/1/2020	4/30/2023
NESTLE HEALTH SCIENCE	1/1/2021	12/31/9999
NEURELIS	10/1/2020	12/31/9999
NEUROCRINE BIOSCIENCES INC	1/1/2020	12/31/9999
NODEN PHARMA USA	1/1/2020	12/31/9999
NOVARTIS	7/1/2020	12/31/9999
NOVARTIS GENE THERAPY	1/1/2023	12/31/9999
NOVEN THERAPEUTICS LLC	1/1/2021	12/31/9999
NOVO NORDISK	4/1/2020	12/31/9999
OCTAPHARMA USA	7/1/2021	12/31/9999
OPKO PHARMACEUTICALS LLC	1/1/2020	12/31/9999
OPTINOSE US, INC	1/1/2020	12/31/9999
OREXO	7/1/2019	12/31/9999
ORGANON	12/1/2022	12/31/9999
OTSUKA	1/1/2021	12/31/9999
OYSTER POINT PHARMA INC	7/1/2022	12/31/9999
PADAGIS US LLC	1/1/2020	12/31/9999
PARATEK PHARMACEUTICALS, INC	1/1/2020	12/31/9999
PARI RESPIRATORY	1/1/2020	12/31/9999
PFIZER US PHARM	7/1/2021	12/31/9999
PHARMING HEALTHCARE INC	1/1/2020	12/31/9999
PIERRE FABRE PHARMA INC	1/1/2020	12/31/9999
PURDUE PHARMA	10/1/2019	12/31/9999
RADIUS HEALTH INC	1/1/2020	12/31/9999
RB HEALTH (US) LLC	1/1/2020	12/31/9999
RECORDATI RARE DISEASES	1/1/2023	12/31/2025
REDHILL BIOPHARMA	10/1/2020	12/31/9999
REGENERON PHARMACEUTICALS INC	10/1/2020	8/31/2024

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
RESILIA PHARMACEUTICALS	10/1/2021	12/31/2024
RIGEL	1/1/2022	12/31/9999
ROCHE DIABETES CARE, INC	1/1/2020	12/31/9999
SANDOZ INC	4/1/2020	12/31/9999
SANOFI - AVENTIS	1/1/2023	12/31/9999
SCILEX PHARMACEUTICALS INC	7/1/2019	12/31/9999
SEBELA PHARMACEUTICALS INC	1/1/2021	12/31/9999
SECURA BIO	1/1/2021	12/31/9999
SHIONOGI & COMPANY, INC	1/1/2020	12/31/2024
SK LIFE SCIENCE	4/1/2020	12/31/9999
SOBI INC	1/1/2020	12/31/9999
SUN PHARMA INDUSTRIES INC	1/1/2021	12/31/9999
SUNOVION	1/1/2020	12/31/9999
SUPERNUS PHARMACEUTICALS, INC	1/1/2020	12/31/9999
TAKEDA	1/1/2023	12/31/9999
TEVA	1/1/2023	12/31/9999
THEA PHARMA INC	7/1/2022	12/31/9999
THERAPEUTICSMD INC	1/1/2023	12/31/9999
TOLMAR, INC	10/1/2020	12/31/9999
TRAVERE THERAPEUTICS INC	1/1/2020	12/31/9999
TRIS PHARMA	1/1/2020	11/30/2024
TRIVIDIA HEALTH	1/1/2020	12/31/9999
UCB INC	1/1/2022	12/31/2025
UPSHER-SMITH	1/1/2020	12/31/9999
UROVANT	8/1/2021	12/31/9999
VALINOR PHARMA	11/1/2023	12/31/9999
VELOXIS PHARMACEUTICALS	1/1/2020	12/31/9999
VERTICAL PHARMACEUTICALS	1/1/2020	12/31/9999
VIFOR PHARMA, INC	1/1/2020	3/31/2025
VISTAPHARM	10/1/2021	12/31/9999
VIVUS	1/1/2020	12/31/9999
WOMENS CHOICE PHARMACEUTICALS	1/1/2020	12/31/9999
XERIS	3/1/2020	12/31/9999
ZIMMER US, INC	1/1/2020	12/31/9999

Table 3 below provides the value for each individual SRA. Table 3 is sorted by descending contract value. Table

3 Column Definitions:

- Manufacturer Name - The name of the entity Anthem Blue Cross and Blue Shield Healthcare Solutions has contracted within the SRA.
- Amount Plan Paid for Products During Contract Term - The amount paid for all drugs subject to a manufacturer’s SRA during CY 2022.
  - Example: Drug “A” was subject to an SRA from 06/01/2022 to 03/31/2023. This column would include the amount paid for Drug “A” for claims paid from 01/01/2023 to 03/31/2023.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2023.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2023 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2023 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.

**Table 3**

Supplemental Rebate Agreements during CY 2023				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
Manufacturer 1	\$15,800,377.87	\$15,800,377.87	\$1,098.95	\$1,098.95
Manufacturer 2	\$13,250,619.11	\$13,250,619.11	\$391,408.32	\$320,556.26
Manufacturer 3	\$12,233,444.00	\$12,233,457.79	\$2,044,213.51	\$1,957,514.22
Manufacturer 4	\$9,528,128.33	\$9,528,128.33	\$37,033.07	\$39,895.47
Manufacturer 5	\$9,147,657.91	\$9,147,678.23	\$812,222.59	\$790,053.85
Manufacturer 6	\$6,656,112.36	\$6,656,112.36	\$8,310.44	\$8,190.25
Manufacturer 7	\$5,876,243.20	\$5,876,243.20	\$0.00	\$0.00
Manufacturer 8	\$5,046,735.08	\$5,046,735.08	\$860,619.98	\$858,296.65
Manufacturer 9	\$4,831,874.63	\$4,831,874.63	\$143,029.69	\$140,619.02
Manufacturer 10	\$4,704,772.50	\$4,704,772.50	\$0.00	\$0.00
Manufacturer 11	\$4,449,950.40	\$4,449,950.40	\$0.00	\$0.00
Manufacturer 12	\$3,935,567.81	\$3,935,567.81	\$183,065.64	\$180,883.86
Manufacturer 13	\$3,866,205.89	\$3,866,205.89	\$55,685.45	\$54,350.30
Manufacturer 14	\$2,711,016.61	\$2,711,016.61	\$0.00	\$0.00
Manufacturer 15	\$2,646,599.48	\$2,646,344.32	\$0.00	\$0.00
Manufacturer 16	\$2,490,262.99	\$2,490,262.99	\$74,312.45	\$74,312.49
Manufacturer 17	\$2,014,528.60	\$2,014,528.60	\$434.63	\$21.35
Manufacturer 18	\$1,876,339.29	\$1,876,339.29	\$0.00	\$0.00
Manufacturer 19	\$1,489,957.99	\$1,489,957.99	\$982,547.69	\$981,318.31
Manufacturer 20	\$1,412,489.02	\$1,412,489.02	\$621.60	\$439.28
Manufacturer 21	\$1,317,765.42	\$1,317,757.17	\$0.00	\$0.00
Manufacturer 22	\$1,256,610.07	\$1,256,610.07	\$34,600.53	\$34,600.54
Manufacturer 23	\$1,127,596.88	\$1,127,596.88	\$0.00	\$0.00

Manufacturer 24	\$876,350.16	\$876,350.16	\$0.00	\$0.00
Manufacturer 25	\$819,911.35	\$819,911.35	\$0.00	\$0.00
Manufacturer 26	\$814,213.86	\$814,213.86	\$0.00	\$0.00
Manufacturer 27	\$792,674.15	\$792,674.15	\$152,403.45	\$143,204.93
Manufacturer 28	\$670,850.11	\$670,850.11	\$0.00	\$0.00
Manufacturer 29	\$642,818.45	\$643,106.41	\$11,712.24	\$11,642.73
Manufacturer 30	\$629,186.45	\$629,186.45	\$11.14	\$11.13
Manufacturer 31	\$599,427.28	\$599,427.28	\$3,929.30	\$3,929.99
Manufacturer 32	\$597,990.95	\$597,990.95	\$0.00	\$0.00
Manufacturer 33	\$578,489.01	\$578,489.01	\$0.00	\$0.00
Manufacturer 34	\$575,543.58	\$575,543.58	\$482,101.01	\$451,289.03
Manufacturer 35	\$556,175.01	\$556,175.01	\$0.00	\$0.00
Manufacturer 36	\$555,688.88	\$555,688.88	\$0.00	\$0.00
Manufacturer 37	\$549,567.71	\$549,567.71	\$0.00	\$0.00
Manufacturer 38	\$473,079.57	\$473,079.57	\$0.00	\$0.00
Manufacturer 39	\$473,079.57	\$473,079.57	\$0.00	\$0.00
Manufacturer 40	\$453,494.42	\$453,499.77	\$0.00	\$0.00
Manufacturer 41	\$426,444.02	\$426,435.18	\$140,116.69	\$135,471.77
Manufacturer 42	\$398,140.52	\$398,140.52	\$0.00	\$0.00
Manufacturer 43	\$396,387.13	\$396,387.13	\$46,478.47	\$46,244.28
Manufacturer 44	\$389,804.66	\$389,804.66	\$0.00	\$0.00
Manufacturer 45	\$362,887.41	\$362,887.41	\$0.00	\$0.00
Manufacturer 46	\$359,878.31	\$359,878.31	\$0.00	\$0.00
Manufacturer 47	\$352,070.48	\$352,070.48	\$0.00	\$0.00
Manufacturer 48	\$328,729.89	\$328,729.89	\$100,833.98	\$100,152.66
Manufacturer 49	\$322,867.35	\$322,867.35	\$0.00	\$0.00
Manufacturer 50	\$255,021.88	\$255,021.88	\$0.00	\$0.00
Manufacturer 51	\$227,642.20	\$227,642.20	\$0.00	\$0.00
Manufacturer 52	\$220,293.96	\$220,293.96	\$0.00	\$0.00
Manufacturer 53	\$215,765.86	\$215,765.86	\$0.00	\$0.00
Manufacturer 54	\$214,983.16	\$214,983.16	\$0.00	\$0.00
Manufacturer 55	\$213,031.54	\$213,031.54	\$0.00	\$0.00
Manufacturer 56	\$210,984.59	\$210,984.59	\$79,019.52	\$79,868.50
Manufacturer 57	\$194,444.59	\$194,444.59	\$0.00	\$0.00
Manufacturer 58	\$190,394.79	\$190,410.54	\$74,287.43	\$73,276.10
Manufacturer 59	\$179,934.06	\$179,934.06	\$0.00	\$0.00
Manufacturer 60	\$174,645.86	\$174,645.86	\$0.00	\$0.00
Manufacturer 61	\$169,909.06	\$169,909.06	\$0.00	\$0.00
Manufacturer 62	\$167,053.35	\$167,053.35	\$0.00	\$0.00
Manufacturer 63	\$116,193.40	\$116,193.40	\$2,620.43	\$2,503.81

Manufacturer 64	\$109,725.60	\$109,725.60	\$0.00	\$0.00
Manufacturer 65	\$102,923.20	\$102,923.20	\$0.00	\$0.00
Manufacturer 66	\$82,636.52	\$82,636.52	\$0.00	\$0.00
Manufacturer 67	\$69,400.30	\$69,400.30	\$0.00	\$0.00
Manufacturer 68	\$66,183.50	\$66,183.50	\$0.00	\$0.00
Manufacturer 69	\$65,495.75	\$65,495.75	\$0.00	\$0.00
Manufacturer 70	\$64,647.17	\$64,647.17	\$0.00	\$0.00
Manufacturer 71	\$64,092.20	\$64,092.20	\$0.00	\$0.00
Manufacturer 72	\$61,591.30	\$61,591.30	\$0.00	\$0.00
Manufacturer 73	\$60,082.50	\$60,082.50	\$0.00	\$0.00
Manufacturer 74	\$59,594.85	\$59,594.85	\$0.00	\$0.00
Manufacturer 75	\$56,075.10	\$56,075.10	\$0.00	\$0.00
Manufacturer 76	\$50,101.88	\$50,101.88	\$0.00	\$0.00
Manufacturer 77	\$49,645.96	\$49,645.96	\$0.00	\$0.00
Manufacturer 78	\$42,611.98	\$42,601.98	\$0.00	\$0.00
Manufacturer 79	\$42,611.98	\$42,601.98	\$0.00	\$0.00
Manufacturer 80	\$37,671.12	\$37,671.12	\$0.00	\$0.00
Manufacturer 81	\$36,872.70	\$36,872.70	\$0.00	\$0.00
Manufacturer 82	\$35,546.10	\$35,546.10	\$0.00	\$0.00
Manufacturer 83	\$32,745.31	\$32,745.31	\$0.00	\$0.00
Manufacturer 84	\$31,910.56	\$31,910.56	\$0.00	\$0.00
Manufacturer 85	\$29,839.42	\$29,839.42	\$291.06	\$245.52
Manufacturer 86	\$29,406.16	\$29,406.16	\$0.00	\$0.00
Manufacturer 87	\$28,511.29	\$28,511.29	\$0.00	\$0.00
Manufacturer 88	\$25,707.61	\$25,707.61	\$3,865.08	\$3,865.00
Manufacturer 89	\$23,668.66	\$23,668.66	\$0.00	\$0.00
Manufacturer 90	\$23,626.90	\$23,626.90	\$0.00	\$0.00
Manufacturer 91	\$21,045.55	\$21,045.55	\$0.00	\$0.00
Manufacturer 92	\$20,504.46	\$20,504.46	\$0.00	\$0.00
Manufacturer 93	\$19,706.74	\$19,706.74	\$0.00	\$0.00
Manufacturer 94	\$18,733.86	\$18,733.86	\$0.00	\$0.00
Manufacturer 95	\$18,591.20	\$18,591.20	\$0.00	\$0.00
Manufacturer 96	\$17,993.57	\$17,993.57	\$0.00	\$0.00
Manufacturer 97	\$17,810.86	\$17,810.86	\$0.00	\$0.00
Manufacturer 98	\$16,291.91	\$16,291.91	\$0.00	\$0.00
Manufacturer 99	\$13,744.55	\$13,744.55	\$0.00	\$0.00
Manufacturer 100	\$13,423.04	\$13,423.04	\$0.00	\$0.00
Manufacturer 101	\$12,472.94	\$12,472.94	\$0.00	\$0.00
Manufacturer 102	\$11,719.34	\$11,719.34	\$0.00	\$0.00
Manufacturer 103	\$10,295.43	\$10,295.43	\$0.00	\$0.00

Manufacturer 104	\$8,366.12	\$8,366.12	\$0.00	\$0.00
Manufacturer 105	\$6,811.05	\$6,811.05	\$0.00	\$0.00
Manufacturer 106	\$6,751.77	\$6,751.77	\$0.00	\$0.00
Manufacturer 107	\$6,347.06	\$6,347.06	\$0.00	\$0.00
Manufacturer 108	\$5,814.10	\$5,814.10	\$0.00	\$0.00
Manufacturer 109	\$5,621.33	\$5,621.33	\$0.00	\$0.00
Manufacturer 110	\$5,231.40	\$5,231.40	\$0.00	\$0.00
Manufacturer 111	\$5,211.78	\$5,211.78	\$0.00	\$0.00
Manufacturer 112	\$5,108.55	\$5,108.55	\$0.00	\$0.00
Manufacturer 113	\$4,645.08	\$4,645.08	\$0.00	\$0.00
Manufacturer 114	\$3,997.49	\$3,997.49	\$0.00	\$0.00
Manufacturer 115	\$3,699.13	\$3,699.13	\$0.00	\$0.00
Manufacturer 116	\$3,652.87	\$3,652.87	\$0.00	\$0.00
Manufacturer 117	\$3,539.95	\$3,539.95	\$1,078.91	\$1,078.91
Manufacturer 118	\$2,267.16	\$2,267.16	\$0.00	\$0.00
Manufacturer 119	\$1,801.15	\$1,801.15	\$0.00	\$0.00
Manufacturer 120	\$1,484.09	\$1,484.09	\$0.00	\$0.00
Manufacturer 121	\$1,469.11	\$1,469.11	\$0.00	\$0.00
Manufacturer 122	\$1,261.79	\$1,261.79	\$0.00	\$0.00
Manufacturer 123	\$824.79	\$824.79	\$0.00	\$0.00
Manufacturer 124	\$795.91	\$795.91	\$0.00	\$0.00
Manufacturer 125	\$696.92	\$696.92	\$0.00	\$0.00
Manufacturer 126	\$504.18	\$504.18	\$0.00	\$0.00
Manufacturer 127	\$501.14	\$501.14	\$0.00	\$0.00
Manufacturer 128	\$336.42	\$336.42	\$31.35	\$31.36
Manufacturer 129	\$83.51	\$83.51	\$0.00	\$0.00
Manufacturer 130	\$23.02	\$23.02	\$0.00	\$0.00
Manufacturer 131	\$2.95	\$2.95	\$0.00	\$0.00
Manufacturer 132	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 133	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 134	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 135	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 136	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 137	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 138	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 139	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 140	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 141	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 142	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 143	\$0.00	\$0.00	\$0.00	\$0.00

Manufacturer 144	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 145	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 146	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 147	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 148	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 149	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 150	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 151	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 152	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 153	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 154	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 155	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 156	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 157	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 158	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 159	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 160	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 161	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 162	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 163	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 164	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 165	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 166	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 167	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 168	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 169	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 170	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 171	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 172	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 173	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 174	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 175	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 176	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 177	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 178	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 179	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 180	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 181	\$0.00	\$0.00	\$0.00	\$0.00
Manufacturer 182	\$0.00	\$0.00	\$0.00	\$0.00

The next two tables provide additional information as required by Nevada Revised Statutes 422.4053 (3)(b). Table 4 below provides the values and total amounts of dispensing fees paid by Anthem Blue Cross and Blue Shield Healthcare Solutions to pharmacies.

Table 4 Column Definitions:

- Retail 30 Days – Dispensing fee cost for 0–30-day supplies at a retail location
- Retail >30 Days – Dispensing fee cost for >30-day supplies at a retail location
- Mail Order – Dispensing fee cost for mail order pharmacies
- Specialty – Dispensing fees cost for specialty pharmacies

Table 4

Dispensing Fees during CY 2023				
Type of Dispensing Fee:	Retail 30 Days	Retail >30 Days	Mail Order	Specialty
Dispensing Fee	\$0.10	\$0.07	\$0.00	\$0.14
Totals	\$298,236	\$1,250	\$0	\$14,007
Grand Total	\$313,493			

Table 5 below provides a summary of measures employed by the pharmacy benefit manager contracted by Anthem Blue Cross and Blue Shield Healthcare Solutions to control outpatient prescription drug costs.

Table 5 Row Definitions:

- Utilization Management – Measures to control use of pharmacy services for medical necessity and appropriateness to provide efficacious and cost-effective medications. Examples of utilization management include but not limited to prior authorization, step therapy, and quantity limits.
- Prior Authorization – Is a prospective review for an approval for the use of a medication.
- Step Therapy – Is a utilization management program that requires a patient to try a lower cost medication before stepping up to a similar-acting more expensive medication.
- Quantity limits – Limits medication use to the maximum dose of a medication.
- Pharmacy Networks – Is a group of pharmacies contracted with the payer where patients can fill medications.
- Preferred Drug List – Is a list of preferred medications that requires a patient to try the preferred medication before using a non-preferred medication.
- Prospective Drug Utilization Review (ProDUR) Activities – ProDUR activities are automated, structured, ongoing review of prescribing, dispensing and use of medications.



Table 5

<b>Measures to Control Costs during CY 2023</b>		
Utilization Management	Prior Authorization	Yes
	Step Therapy	Yes
	Quantity Limits	Yes
Pharmacy Networks		Yes
Preferred Drug List		Yes
ProDUR Activities		Yes

**ATTACHMENT B**  
**Health Plan of Nevada**

### **Supplemental Rebate Agreement Report Calendar Year 2023**

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid Drug Rebate Program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal Unit Rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter into separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies and contracted Managed Care Organizations (MCOs) to ensure preferred status on the respective Preferred Drug Lists (PDL).

Generally, SRAs are in effect for one calendar year beginning on January 1<sup>st</sup> and terminating on December 31<sup>st</sup>. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new National Drug Codes released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31<sup>st</sup> end date such as a product moving to non-preferred status or to coincide with planned Pharmacy & Therapeutics Committee reviews and recommendations.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- "Percentage of WAC" - set percentage of the drug's published wholesale acquisition cost (WAC).
- "GNUP" (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
  - In the event a drug's WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
  - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer's SRA with UnitedHealthcare Health Plan of Nevada Medicaid through its Pharmacy Benefit Manager (PBM).



UnitedHealthcare Health Plan of Nevada Medicaid had 93 SRAs in place that were in effect during Calendar Year 2023 (January 1, 2023 – December 31, 2023) (hereinafter referred to as CY 2023). Table 1 below summarizes the agreements.

Table 1 Row Definitions:

- Number of Contracts - The count of signed SRAs that were in force during some period within CY 2023.
- Number of Unique Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within CY 2023.
- Amount Plan Paid for Products During Contract Term - The amount UnitedHealthcare Health Plan of Nevada Medicaid paid for all drug utilization subject to a manufacturer’s SRA during CY 2023.
  - Example: Drug “A” was subject to an SRA from 1/01/2023 to 12/31/2023 would include the amount paid for Drug “A” for claims paid from 1/01/2023 to 12/31/2023.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract – The amount Health Plan of Nevada paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2023.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2023 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2023 From manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.
  - Example: Manufacturer B was invoiced \$100.00 for supplemental rebates in November 2022 and remitted payment in January 2023. This column would include the payment since it was made during CY 2023.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products - The result of dividing the contract value by the amount the plan paid pharmacies/providers for contracted drugs, expressed as a percentage.

Table 1

<b>Summary of Supplemental Rebate Agreements during CY 2023</b>	
<b>Number of Contracts</b>	93
<b>Number of Unique Manufacturers Under Contract</b>	47
<b>Amount Plan Paid for Products During Contract Term</b>	\$46,241,101.37
<b>Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term</b>	\$46,241,101.37
<b>Total Supplemental Rebates Invoiced</b>	\$9,814,275.57
<b>Total Supplemental Rebates Collected</b>	\$9,620,335.90
<b>Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products</b>	21.22%



Table 2 below lists the SRAs in place during CY 2023. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity UnitedHealthcare Health Plan of Nevada Medicaid and its PBM have contracted with in the SRA.
- Effective Date - The start date of the SRA.
- Term Date - The end date of the SRA.

**Table 2**

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
Abbott	1/1/2023	12/31/2023
AbbVie #1	1/1/2023	12/31/2023
AbbVie #2	1/1/2023	12/31/2023
AbbVie #3	1/1/2023	12/31/2023
AbbVie #4	1/1/2023	12/31/2023
ALKERMES	1/1/2023	12/31/2023
AMGEN #1	1/1/2023	12/31/2023
AMGEN #2	1/1/2023	12/31/2023
AMGEN #3	1/1/2023	12/31/2023
AMGEN #4	1/1/2023	12/31/2023
AMGEN #5	1/1/2023	12/31/2023
AMGEN #6	1/1/2023	12/31/2023
AMGEN #7	1/1/2023	12/31/2023
AMGEN #8	1/1/2023	12/31/2023
AMGEN #9	1/1/2023	12/31/2023
AMGEN #10	1/1/2023	12/31/2023
ASCENDIS	1/1/2023	12/31/2023
ASEGUA	1/1/2023	12/31/2023
ASTELLAS #1	1/1/2023	12/31/2023
ASTELLAS #2	1/1/2023	12/31/2023
ASTRA ZENECA #1	1/1/2023	12/31/2023
ASTRA ZENECA #2	1/1/2023	12/31/2023
BECTON DICKINSON #1	1/1/2023	12/31/2023
BECTON DICKINSON #2	1/1/2023	12/31/2023

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
BECTON DICKINSON #3	1/1/2023	12/31/2023
BIOGEN	1/1/2023	12/31/2023
BIOHAVEN	1/1/2023	12/31/2023
BIOVENTUS	1/1/2023	12/31/2023
BRAINTREE	1/1/2023	12/31/2023
DEXCOM	1/1/2023	12/31/2023
DEY	1/1/2023	12/31/2023
ELI LILLY #1	1/1/2023	12/31/2023
ELI LILLY #2	1/1/2023	12/31/2023
ELI LILLY #3	1/1/2023	12/31/2023
ELI LILLY #4	1/1/2023	12/31/2023
ELI LILLY #5	1/1/2023	12/31/2023
ELI LILLY #6	1/1/2023	12/31/2023
ELI LILLY #7	1/1/2023	12/31/2023
FERRING	1/1/2023	12/31/2023
GENENTECH #1	1/1/2023	12/31/2023
GENENTECH #2	1/1/2023	12/31/2023
HIKMA	1/1/2023	12/31/2023
INDIVIOR	1/1/2023	12/31/2023
JOHNSON & JOHNSON #1	1/1/2023	12/31/2023
JOHNSON & JOHNSON #2	1/1/2023	12/31/2023
JOHNSON & JOHNSON #3	1/1/2023	12/31/2023
JOHNSON & JOHNSON #4	1/1/2023	12/31/2023
JOHNSON & JOHNSON #5	1/1/2023	12/31/2023
JOHNSON & JOHNSON #6	1/1/2023	12/31/2023
LIFESCAN	1/1/2023	12/31/2023
MERCK & CO INC #1	1/1/2023	12/31/2023
MERCK & CO INC #2	1/1/2023	12/31/2023
MERCK & CO INC #3	1/1/2023	12/31/2023
NEUROCRINE	1/1/2023	12/31/2023
NOVARTIS #1	1/1/2023	12/31/2023
NOVARTIS #2	1/1/2023	12/31/2023
NOVO NORDISK	1/1/2023	12/31/2023
ORGANON #1	1/1/2023	12/31/2023
ORGANON #2	1/1/2023	12/31/2023
OTSUKA #1	1/1/2023	12/31/2023



Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
OTSUKA #2	1/1/2023	12/31/2023
PARATEK	1/1/2023	12/31/2023
PFIZER #1	1/1/2023	12/31/2023
PFIZER #2	1/1/2023	12/31/2023
PFIZER #3	1/1/2023	12/31/2023
PFIZER #4	1/1/2023	12/31/2023
PIERRE	1/1/2023	12/31/2023
RADIUS HEALTH	1/1/2023	12/31/2023
REDHILL	1/1/2023	12/31/2023
REGENERON	1/1/2023	12/31/2023
RELYPSA	1/1/2023	12/31/2023
SANDOZ	1/1/2023	12/31/2023
SANOFI-AVE #1	1/1/2023	12/31/2023
SANOFI-AVE #2	1/1/2023	12/31/2023
SANOFI-AVE #3	1/1/2023	12/31/2023
SANOFI-AVE #4	1/1/2023	12/31/2023
SANOFI-AVE #5	1/1/2023	12/31/2023
SANOFI-AVE #6	1/1/2023	12/31/2023
SHIONOGI PHARMA	1/1/2023	12/31/2023
SUN #1	1/1/2023	12/31/2023
SUN #2	1/1/2023	12/31/2023
SUNOVION	1/1/2023	12/31/2023
TAKEDA	1/1/2023	12/31/2023
TEVA NEU	1/1/2023	12/31/2023
UCB	1/1/2023	12/31/2023
USWM LLC	1/1/2023	12/31/2023
VALINOR	1/1/2023	12/31/2023
VIIV #1	1/1/2023	12/31/2023
VIIV #2	1/1/2023	12/31/2023
VIIV #3	1/1/2023	12/31/2023
VIIV #4	1/1/2023	12/31/2023
XERIS #1	1/1/2023	12/31/2023
XERIS #2	1/1/2023	12/31/2023
XERIS #3	1/1/2023	12/31/2023
XERIS #4	1/1/2023	12/31/2023



Table 3 below provides the value for each individual SRA. Table 3 is sorted by descending contract value. Table

3 Column Definitions:

Manufacturer Name - The blinded name of the entity UnitedHealthcare Health Plan of Nevada Medicaid and its PBM have contracted within the SRA.

- Amount Plan Paid for Products During Contract Term - The amount paid for all drugs subject to a manufacturer’s SRA during CY 2023.
  - Example: Drug “A” was subject to an SRA from 1/01/2023 to 12/31/2023. This column would include the amount paid for Drug “A” for claims paid from 1/01/2023 to 12/31/2023.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2023.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2023 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2023 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.

**Table 3**

<b>Supplemental Rebate Agreements during CY 2023</b>				
<b>Manufacturer Name</b>	<b>Amount Plan Paid for Products During Contract Term</b>	<b>Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term</b>	<b>Total Supplemental Rebates Invoiced</b>	<b>Total Supplemental Rebates Collected</b>
NVMCO HPN SRA 3	\$ 17,409,254.23	\$ 17,409,254.23	\$ 3,923,998.61	\$ 3,856,267.14
NVMCO HPN SRA 6	\$ 3,586,888.76	\$ 3,586,888.76	\$ 303,873.62	\$ 316,339.35
NVMCO HPN SRA 38	\$ 3,265,921.45	\$ 3,265,921.45	\$ 300,098.56	\$ 251,049.84
NVMCO HPN SRA 45	\$ 2,971,751.01	\$ 2,971,751.01	\$ 32,791.70	\$ 32,399.53
NVMCO HPN SRA 29	\$ 2,624,602.38	\$ 2,624,602.38	\$ 74,418.47	\$ 68,345.81
NVMCO HPN SRA 30	\$ 2,399,408.31	\$ 2,399,408.31	\$ 1,478,111.63	\$ 1,416,988.94
NVMCO HPN SRA 24	\$ 2,304,572.67	\$ 2,304,572.67	\$ 2,041,187.29	\$ 2,046,459.67
NVMCO HPN SRA 36	\$ 2,041,537.96	\$ 2,041,537.96	\$ 341,114.11	\$ 335,538.22
NVMCO HPN SRA 33	\$ 1,753,437.19	\$ 1,753,437.19	\$ 107,149.57	\$ 107,685.99
NVMCO HPN SRA 25	\$ 1,291,835.92	\$ 1,291,835.92	\$ 244,209.25	\$ 241,303.05
NVMCO HPN SRA 31	\$ 798,613.77	\$ 798,613.77	\$ 49,205.91	\$ 48,358.41
NVMCO HPN SRA 47	\$ 698,154.19	\$ 698,154.19	\$ 113,538.65	\$ 117,481.32
NVMCO HPN SRA 27	\$ 644,377.50	\$ 644,377.50	\$ 37,235.98	\$ 30,656.58



Supplemental Rebate Agreements during CY 2023				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
NVMCO HPN SRA 9	\$ 608,544.00	\$ 608,544.00	\$ 59,280.00	\$ 59,310.96
NVMCO HPN SRA 22	\$ 606,532.96	\$ 606,532.96	\$ 305,983.12	\$ 307,072.08
NVMCO HPN SRA 35	\$ 561,880.58	\$ 561,880.58	\$ 51,356.74	\$ 52,189.97
NVMCO HPN SRA 26	\$ 396,370.02	\$ 396,370.02	\$ 40,640.29	\$ 39,989.72
NVMCO HPN SRA 10	\$ 386,401.96	\$ 386,401.96	\$ 30,913.59	\$ 27,734.92
NVMCO HPN SRA 28	\$ 285,150.21	\$ 285,150.21	\$ 51,428.23	\$ 50,328.78
NVMCO HPN SRA 40	\$ 243,003.88	\$ 243,003.88	\$ 15,555.25	\$ 15,503.62
NVMCO HPN SRA 16	\$ 228,775.63	\$ 228,775.63	\$ 13,958.91	\$ 14,142.82
NVMCO HPN SRA 17	\$ 228,723.30	\$ 228,723.30	\$ 587.72	\$ 552.37
NVMCO HPN SRA 18	\$ 103,000.37	\$ 103,000.37	\$ 41,364.21	\$ 40,467.13
NVMCO HPN SRA 39	\$ 97,208.40	\$ 97,208.40	\$ 1,900.47	\$ 1,898.79
NVMCO HPN SRA 34	\$ 81,631.89	\$ 81,631.89	\$ 20,289.99	\$ 20,405.09
NVMCO HPN SRA 46	\$ 78,608.62	\$ 78,608.62	\$ 17,115.39	\$ 15,643.62
NVMCO HPN SRA 43	\$ 68,709.13	\$ 68,709.13	\$ 24,129.50	\$ 24,116.95
NVMCO HPN SRA 23	\$ 68,061.26	\$ 68,061.26	\$ 9,209.76	\$ 173.13
NVMCO HPN SRA 32	\$ 62,770.50	\$ 62,770.50	\$ 23,176.80	\$ 23,177.70
NVMCO HPN SRA 5	\$ 49,061.60	\$ 49,061.60	\$ 9,569.00	\$ 9,569.00
NVMCO HPN SRA 15	\$ 47,541.00	\$ 47,541.00	\$ 11,160.46	\$ 10,517.26
NVMCO HPN SRA 13	\$ 37,345.48	\$ 37,345.48	\$ 9,179.11	\$ 8,593.61
NVMCO HPN SRA 1	\$ 31,878.04	\$ 31,878.04	\$ 4,536.76	\$ 4,447.29
NVMCO HPN SRA 14	\$ 30,697.45	\$ 30,697.45	\$ 3,776.64	\$ 3,776.63
NVMCO HPN SRA 37	\$ 23,762.83	\$ 23,762.83	\$ 2,353.92	\$ 2,348.42
NVMCO HPN SRA 12	\$ 23,757.90	\$ 23,757.90	\$ 4,869.12	\$ 4,867.63
NVMCO HPN SRA 44	\$ 23,375.97	\$ 23,375.97	\$ 1,900.18	\$ 1,900.18
NVMCO HPN SRA 4	\$ 20,837.62	\$ 20,837.62	\$ 427.45	\$ -
NVMCO HPN SRA 42	\$ 19,561.41	\$ 19,561.41	\$ 4,961.28	\$ 4,964.02
NVMCO HPN SRA 20	\$ 18,550.28	\$ 18,550.28	\$ 3,267.31	\$ 3,267.29
NVMCO HPN SRA 2	\$ 8,287.50	\$ 8,287.50	\$ 998.75	\$ 999.19
NVMCO HPN SRA 41	\$ 7,999.92	\$ 7,999.92	\$ 2,341.32	\$ 2,341.32
NVMCO HPN SRA 8	\$ 1,396.00	\$ 1,396.00	\$ 231.17	\$ 238.11

Supplemental Rebate Agreements during CY 2023				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
NVMCO HPN SRA 21	\$ 693.92	\$ 693.92	\$ 136.68	\$ 131.74
NVMCO HPN SRA 19	\$ 626.40	\$ 626.40	\$ 120.96	\$ 120.57
NVMCO HPN SRA 7	\$ -	\$ -	\$ 622.14	\$ 622.14
NVMCO HPN SRA 11	\$ -	\$ -	\$ -	\$ 50.00

The next two tables provide additional information as required by NRS 422.4053 (3)(b). Table 4 below provides the values and total amounts of dispensing fees paid by UnitedHealthcare Health Plan of Nevada Medicaid and its PBM to pharmacies.

Table 4 Column Definitions:

- Retail 30 Days – Dispensing fee cost for 0–30-day supplies at a retail location
- Retail >30 Days – Dispensing fee cost for >30-day supplies at a retail location
- Mail Order – Dispensing fee cost for mail order pharmacies
- Specialty – Dispensing fees cost for specialty pharmacies

**Table 4**

Dispensing Fees during CY 2023				
Type of Dispensing Fee:	Retail 30 Days	Retail >30 Days	Mail Order	Specialty
Dispensing Fee	\$7.92	\$10.06	\$8.81	\$34.06
Totals	\$15,524,422.21	\$1,417,490.83	\$617.00	\$263,587.43
Grand Total	\$17,206,117.47			



Table 5 below provides a summary of measures employed by UnitedHealthcare Health Plan of Nevada Medicaid and its PBM to control outpatient prescription drug costs.

Table 5 Row Definitions:

- Utilization Management – Measures to control use of pharmacy services for medical necessity and appropriateness to provide efficacious and cost-effective medications. Examples of utilization management include but not limited to prior authorization, step therapy, and quantity limits.
- Prior Authorization – Is a prospective review for an approval for the use of a medication.
- Step Therapy – Is a utilization management program that requires a patient to try a lower cost medication before stepping up to a similar-acting more expensive medication.
- Quantity limits – Limits medication use to the maximum dose of a medication.
- Pharmacy Networks – Is a group of pharmacies contracted with the payer where patients can fill medications.
- Preferred Drug List – Is a list of preferred medications that requires a patient to try the preferred medication before using a non-preferred medication.
- Prospective Drug Utilization Review (ProDUR) Activities – ProDUR activities are automated, structured, ongoing review of prescribing, dispensing and use of medications.

**Table 5**

<b>Measures to Control Costs during CY 2023</b>		
Utilization Management	Prior Authorization	Yes
	Step Therapy	Yes
	Quantity Limits	Yes
Pharmacy Networks		Yes
Preferred Drug List		Yes
ProDUR Activities		Yes

# **ATTACHMENT C**

## **Molina Healthcare**

## Molina Healthcare Supplemental Rebate Agreement Report Calendar Year 2023

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid Drug Rebate Program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal Unit Rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter into separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists (PDL).

Generally, the SRAs are in effect for one calendar year beginning on January 1st and terminating on December 31st. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new National Drug Codes released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31st end date such as a product moving to non-preferred status or to coincide with planned coverage review.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- "Percentage of WAC" - set percentage of the drug's published wholesale acquisition cost (WAC).
- "GNUP" (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
  - In the event a drug's WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
  - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Molina Healthcare Inc. price protection in case the manufacturer raises the drug price during the contract term.
  - The type of calculation used for a particular product is defined within a manufacturer's SRA with the managed care organization.

Molina Healthcare Inc. had 218 SRAs in place that were in effect during Calendar Year 2023 (January 1, 2023 – December 31, 2023 (hereinafter referred to as CY 2023). Table 1 below summarizes the agreements.

Table 1 Row Definitions:

- Number of Contracts - The count of signed SRAs that were in force during some period within CY 2023.
- Number of Unique Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within CY 2023.
- Amount Plan Paid for Products During Contract Term - The amount The Nevada Department of Health and Human Services, DHCFP paid for all drug utilization subject to a manufacturer’s SRA during CY 2023.
  - Example: Drug “A” was subject to an SRA from 04/01/2023 to 12/31/2023 would include the amount paid for Drug “A” for claims paid from 04/01/2023 to 12/31/2023.
- Amount Medicaid Paid to Pharmacies/Providers for Products Under Contract – The amount Medicaid paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during calendar year 2023.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2023 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2023 From manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.
  - Example: Manufacturer B was invoiced \$100.00 for supplemental rebates in November 2022 and remitted payment in January 2023. This column would include the payment since it was made during calendar year 2023.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products - The result of dividing Total Supplemental Rebates Invoiced **by** Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term.

**Table 1**

Summary of Supplemental Rebate Agreements during CY 2023	
<b>Number of Contracts</b>	218
<b>Number of Unique Manufacturers Under Contract</b>	182
<b>Amount Plan Paid for Products During Contract Term</b>	\$36,101,551.36
<b>Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term</b>	\$36,101,551.36
<b>Total Supplemental Rebates Invoiced</b>	\$2,063,507.30
<b>Total Supplemental Rebates Collected</b>	\$1,899,046.80
<b>Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products</b>	5.72%

Table 2 below lists the SRAs in place during CY 2023. The list is sorted alphabetically by manufacturer name and by SRA start dates.

**Table 2 Column Definitions:**

- **Manufacturer Name** - The name of the entity the State has contracted with in the SRA.
- **Effective Date** - The start date of the SRA.
- **Term Date** - The end date of the SRA.

**Table 2**

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
ABBOTT DIABETES CARE	1/1/2020	12/31/9999
ABBVIE INC	1/1/2017	12/31/9999
ABBVIE INC	12/1/2020	12/31/9999
ACORDA THERAPEUTICS INC	1/1/2020	12/31/9999
AERIE	1/1/2020	12/31/9999
AKARX INC	9/1/2020	12/31/9999
AKEBIA THERAPEUTICS INC	1/1/2020	12/31/9999
AKEBIA THERAPEUTICS INC	1/1/2022	12/31/9999
AKORN, INC	1/1/2020	12/31/9999
ALCON LABORATORIES	1/1/2022	12/31/9999
ALEXION PHARMACEUTICALS INC	1/1/2020	12/31/9999
ALFASIGMA USA	1/1/2020	12/31/9999
ALK ABELLO INC	1/1/2020	12/31/9999
ALKERMES INC	4/1/2020	12/31/2025
ALLERGAN PHARM	1/1/2020	8/31/2025
ALLERGAN PHARM	4/1/2020	8/31/2023
ALMATICA	10/1/2020	12/31/9999
ALMIRALL LLC	1/1/2020	12/31/9999
ALVOGEN INC	7/1/2021	12/31/9999
AMAG PHARMACEUTICALS, INC	1/1/2020	12/31/9999
AMARIN	1/1/2020	12/31/9999
AMGEN	1/1/2020	6/30/2023
AMGEN	7/1/2020	12/31/2025
AMGEN	1/1/2023	12/31/9999
AMNEAL PHARMACEUTICALS LLC	1/1/2020	12/31/9999
ANI PHARMACEUTICALS	7/1/2021	12/31/9999
ANTARES PHARMA INC	1/1/2020	12/31/9999
ARBOR	1/1/2020	12/31/9999
ARKRAY USA INC	1/1/2020	12/31/9999
ASCEND THERAPEUTICS US, LLC	1/1/2020	3/31/2025
ASCENDIS PHARMA ENDOCRINOLOGY	11/1/2021	12/31/9999
ASCENSIA DIABETES CARE US INC	1/1/2020	12/31/9999
ASEGUA	1/1/2020	12/31/9999
ASSERTIO	1/1/2020	12/31/2023

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
ASTELLAS PHARMA US	1/1/2020	8/31/2023
ASTELLAS PHARMA US	1/1/2023	12/31/9999
ASTRAZENECA	1/1/2020	12/31/9999
ASTRAZENECA	4/1/2020	12/31/9999
AVANIR PHARMACEUTICALS	1/1/2020	12/31/2024
AVION PHARMACEUTICALS	1/1/2020	12/31/9999
BANNER LIFE SCIENCES	10/1/2020	12/31/9999
BAUSCH & LOMB	10/1/2021	12/31/9999
BAUSCH HEALTH US LLC	1/1/2020	12/31/9999
BAYER	1/1/2020	12/31/9999
BIODELIVERY SCIENCES INT	7/1/2019	12/31/9999
BIOFRONTERA INC	1/1/2020	2/28/2026
BIOGEN	1/1/2020	12/31/9999
BIOHAVEN PHARMACEUTICALS	4/1/2020	8/31/2023
BIOHAVEN PHARMACEUTICALS	1/1/2023	12/31/9999
BIOVENTUS LLC	1/1/2020	12/31/9999
BOEHRINGER INGELHEIM	1/1/2020	12/31/9999
BOEHRINGER INGELHEIM	4/1/2020	12/31/9999
BRISTOL-MYERS SQUIBB	1/1/2020	12/31/9999
BRISTOL-MYERS SQUIBB	4/1/2020	12/31/9999
CATALYST PHARMACEUTICALS	9/1/2023	12/31/9999
CEQR CORPORATION	1/1/2021	12/31/9999
CHIESI USA	1/1/2020	12/31/9999
CLARUS THERAPEUTICS	7/1/2021	12/31/9999
CLOVIS ONCOLOGY INC	1/1/2020	12/31/2023
COHERUS BIOSCIENCES	1/1/2020	8/31/2023
COLLEGIUM PHARMACEUTICALS	7/1/2019	12/31/9999
CORIUM LLC	7/1/2022	12/31/9999
COVIS PHARMA	1/1/2020	12/31/9999
COVIS PHARMA	7/1/2020	12/31/9999
CSL BEHRING LLC	1/1/2020	12/31/9999
CSL BEHRING LLC	4/1/2020	2/28/2025
CUMBERLAND PHARMACEUTICALS	1/1/2020	12/31/9999
CURRAX PHARMACEUTICALS LLC	1/1/2020	12/31/9999
CYCLE PHARMACEUTICALS	1/1/2020	12/31/9999
DEXCOM	1/1/2020	12/31/9999
DIGESTIVE CARE	1/1/2020	12/31/9999
DUCHESNAY USA, INC	1/1/2020	12/31/9999
EISAI INC	1/1/2020	12/31/9999
ELI LILLY & COMPANY	1/1/2020	12/31/2025



Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
ELI LILLY & COMPANY	5/1/2020	12/31/2025
EMBECTA CORP	1/1/2020	12/31/9999
EMD SERONO	7/1/2021	12/31/2026
EMD SERONO	1/1/2022	12/31/2026
EMERGENT DEVICES	1/1/2021	12/31/9999
EMMAUS MEDICAL INC	1/1/2023	12/31/9999
ENDO PHARMACEUTICAL SOLUTIONS	10/1/2019	12/31/9999
ENDO PHARMACEUTICAL SOLUTIONS	7/1/2021	12/31/9999
EPI HEALTH LLC	1/1/2020	1/31/2024
EPI HEALTH LLC	1/1/2021	1/31/2024
ESPERION THERAPEUTICS	4/1/2020	12/31/2025
EXELIXIS INC	1/1/2020	12/31/9999
EXELTIS USA DERMATOLOGY	1/1/2020	12/31/9999
EYEVANCE	1/1/2020	12/31/2024
FERRING	1/1/2020	12/31/9999
FIDIA PHARMA USA INC	1/1/2020	8/31/2024
FRESENIUS KABI	7/1/2021	12/31/9999
FRESENIUS USA	1/1/2020	12/31/2024
GALDERMA	1/1/2021	12/31/9999
GENENTECH	1/1/2020	12/31/2025
GILEAD SCIENCES INC	1/1/2020	12/31/9999
GILEAD SCIENCES INC	7/1/2020	12/31/9999
GREENWICH BIOSCIENCES	1/1/2020	12/31/9999
GREER LABORATORIES, INC	1/1/2020	8/31/2026
GRIFOLS USA, LLC	1/1/2020	12/31/9999
H2 PHARMA	10/1/2023	12/31/9999
HARROW EYE	7/1/2023	12/31/9999
HEMA BIOLOGICS	1/1/2022	12/31/9999
HIKMA AMERICAS	1/1/2020	12/31/9999
HIKMA PHARMACEUTICALS	2/1/2023	12/31/9999
HORIZON MEDICINES LLC	1/1/2020	12/31/9999
HTL-STREFA	4/1/2021	12/31/9999
IMPEL PHARMACEUTICALS	10/1/2021	12/31/9999
INDIVIOR INC	7/1/2019	12/31/2024
INSULET	1/1/2020	12/31/9999
INTUITY MEDICAL	10/1/2021	12/31/9999
IPSEN BIOPHARMACEUTICALS INC	1/1/2020	12/31/9999
IRONSHORE	1/1/2020	12/31/9999
JAZZ	4/1/2020	12/31/2025
JOHNSON and JOHNSON	1/1/2017	8/31/2023

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
JOHNSON and JOHNSON	10/1/2020	12/31/9999
JOHNSON and JOHNSON	1/1/2023	12/31/9999
JOURNEY MEDICAL	9/1/2020	12/31/9999
KALA PHARMACEUTICALS INC	1/1/2020	12/31/2023
KALEO, INC	1/1/2022	12/31/9999
KOWA PHARMACEUTICALS	1/1/2020	12/31/9999
KOWA PHARMACEUTICALS	1/1/2022	12/31/9999
KYOWA KIRIN	1/1/2020	12/31/9999
LEO PHARMA, INC	1/1/2020	12/31/9999
LIFESCAN	1/1/2020	12/31/2025
LUPIN PHARMACEUTICALS, INC	7/1/2021	12/31/9999
MALLINCKRODT	10/1/2019	12/31/9999
MANNKIND CORPORATION	1/1/2020	12/31/9999
MAYNE PHARMA	1/1/2020	12/31/9999
MEDEXUS PHARMA	1/1/2020	12/31/2023
MEDUNIK USA	7/1/2022	12/31/9999
MELINTA THERAPEUTICS LLC	1/1/2020	12/31/9999
MERCK & CO, INC	1/1/2020	12/31/9999
MERCK & CO, INC	10/1/2021	12/31/9999
METUCHEN	1/1/2020	12/31/9999
MILLENNIUM PHARMACEUTICALS	1/1/2021	12/31/9999
MILLICENT	1/1/2020	12/31/9999
MINIMED DISTRIBUTION CORP	1/1/2020	12/31/9999
MISSION	1/1/2020	12/31/9999
MYLAN PHARMACEUTICALS INC	1/1/2020	12/31/9999
MYLAN PHARMACEUTICALS INC	4/1/2020	12/31/9999
MYOVANT	6/1/2022	12/31/9999
NABRIVA	1/1/2020	12/31/9999
NEOS THERAPEUTICS LP	1/1/2020	4/30/2023
NESTLE HEALTH SCIENCE	1/1/2021	12/31/9999
NEURELIS	10/1/2020	12/31/9999
NEUROCRINE BIOSCIENCES INC	1/1/2020	12/31/9999
NODEN PHARMA USA	1/1/2020	12/31/9999
NOVARTIS	1/1/2020	12/31/9999
NOVARTIS	7/1/2020	12/31/9999
NOVARTIS GENE THERAPY	1/1/2023	12/31/9999
NOVEN THERAPEUTICS LLC	1/1/2020	12/31/9999
NOVEN THERAPEUTICS LLC	1/1/2021	12/31/9999
NOVO NORDISK	1/1/2020	12/31/9999
NOVO NORDISK	3/1/2020	9/30/2024

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
NOVO NORDISK	4/1/2020	12/31/9999
OCTAPHARMA USA	7/1/2021	12/31/9999
OPKO PHARMACEUTICALS LLC	1/1/2020	12/31/9999
OPTINOSE US, INC	1/1/2020	12/31/9999
OREXO	7/1/2019	12/31/9999
ORGANON	12/1/2022	12/31/9999
OTSUKA	1/1/2020	12/31/9999
OTSUKA	1/1/2021	12/31/2024
OYSTER POINT PHARMA INC	7/1/2022	12/31/9999
PADAGIS US LLC	1/1/2020	12/31/9999
PARATEK PHARMACEUTICALS, INC	1/1/2020	12/31/9999
PARI RESPIRATORY	1/1/2020	12/31/9999
PFIZER US PHARM	1/1/2020	12/31/9999
PFIZER US PHARM	7/1/2021	12/31/9999
PHARMING HEALTHCARE INC	1/1/2020	12/31/9999
PIERRE FABRE PHARMA INC	1/1/2020	12/31/9999
PURDUE PHARMA	10/1/2019	12/31/9999
RADIUS HEALTH INC	1/1/2020	12/31/9999
RB HEALTH (US) LLC	1/1/2020	12/31/9999
RECORDATI RARE DISEASES	1/1/2023	12/31/2025
REDHILL BIOPHARMA	1/1/2020	12/31/9999
REDHILL BIOPHARMA	10/1/2020	12/31/2024
REGENERON PHARMACEUTICALS INC	10/1/2020	8/31/2024
RESILIA PHARMACEUTICALS	10/1/2021	12/31/2024
RIGEL	1/1/2022	12/31/9999
ROCHE DIABETES CARE, INC	1/1/2020	12/31/9999
SANDOZ INC	4/1/2020	12/31/9999
SANOFI - AVENTIS	7/1/2021	12/31/9999
SANOFI - AVENTIS	1/1/2023	12/31/9999
SCILEX PHARMACEUTICALS INC	7/1/2019	12/31/9999
SEBELA PHARMACEUTICALS INC	1/1/2021	12/31/9999
SECURA BIO	1/1/2021	12/31/9999
SHIONOGI & COMPANY, INC	1/1/2020	12/31/2024
SK LIFE SCIENCE	4/1/2020	12/31/9999
SOBI INC	1/1/2020	12/31/9999
SUN PHARMA INDUSTRIES INC	1/1/2020	12/31/9999
SUN PHARMA INDUSTRIES INC	1/1/2021	12/31/9999
SUNOVION	1/1/2020	12/31/9999
SUPERNUS PHARMACEUTICALS, INC	1/1/2020	12/31/9999
TAKEDA	10/1/2019	9/30/2023

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
TAKEDA	4/1/2020	12/31/9999
TAKEDA	1/1/2023	12/31/9999
TEVA	1/1/2020	1/31/2024
TEVA	4/1/2020	12/31/9999
TEVA	1/1/2023	12/31/9999
THEA PHARMA INC	7/1/2022	12/31/9999
THERAPEUTICSMD INC	1/1/2020	12/31/2023
THERAPEUTICSMD INC	1/1/2023	12/31/9999
TOLMAR, INC	10/1/2020	12/31/9999
TRAVERE THERAPEUTICS INC	1/1/2020	12/31/9999
TRIS PHARMA	1/1/2020	11/30/2024
TRIVIDIA HEALTH	1/1/2020	12/31/9999
UCB INC	1/1/2022	12/31/2025
UPSHER-SMITH	1/1/2020	12/31/9999
UROVANT	8/1/2021	12/31/9999
VALINOR PHARMA	11/1/2023	12/31/9999
VELOXIS PHARMACEUTICALS	1/1/2020	12/31/9999
VERTICAL PHARMACEUTICALS	1/1/2020	12/31/9999
VIFOR PHARMA, INC	1/1/2020	3/31/2025
VISTAPHARM	10/1/2021	12/31/9999
VIVUS	1/1/2020	12/31/9999
WOMENS CHOICE PHARMACEUTICALS	1/1/2020	12/31/9999
XERIS	3/1/2020	12/31/9999
ZIMMER US, INC	1/1/2020	12/31/9999

Table 3 below provides the value for each individual SRA. Table 3 is sorted by descending contract value. Table

3 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted within the SRA.
- Amount Plan Paid for Products During Contract Term - The amount paid for all drugs subject to a manufacturer’s SRA during CY 2023.
  - Example: Drug “A” was subject to an SRA from 06/01/2022 to 03/31/2023. This column would include the amount paid for Drug “A” for claims paid from 01/01/2023 to 03/31/2023.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2023.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2023 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2023 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.

**Table 3**

Supplemental Rebate Agreements during CY 2023				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
Manufacturer 1	\$3,150,849	\$3,150,849	\$679,625	\$607,057
Manufacturer 2	\$375,048	\$375,048	\$251,997	\$251,256
Manufacturer 3	\$2,185,619	\$2,185,619	\$215,074	\$181,691
Manufacturer 4	\$257,119	\$257,119	\$213,483	\$199,871
Manufacturer 5	\$760,629	\$760,629	\$104,997	\$99,874
Manufacturer 6	\$1,658,293	\$1,658,293	\$83,348	\$80,814
Manufacturer 7	\$31,484	\$31,484	\$73,343	\$72,131
Manufacturer 8	\$437,941	\$437,941	\$72,000	\$71,840
Manufacturer 9	\$1,118,251	\$1,118,251	\$67,320	\$67,321
Manufacturer 10	\$1,017,710	\$1,017,710	\$64,682	\$64,498
Manufacturer 11	\$872,243	\$872,243	\$52,696	\$37,725
Manufacturer 12	\$2,654,841	\$2,654,841	\$48,105	\$40,663
Manufacturer 13	\$317,163	\$317,163	\$27,362	\$27,290
Manufacturer 14	\$2,780,938	\$2,780,938	\$26,654	\$24,799
Manufacturer 15	\$50,290	\$50,290	\$14,624	\$14,506
Manufacturer 16	\$300,764	\$300,764	\$13,866	\$9,668
Manufacturer 17	\$607,899	\$607,899	\$10,357	\$9,981
Manufacturer 18	\$46,486	\$46,486	\$9,802	\$9,800
Manufacturer 19	\$28,175	\$28,175	\$8,997	\$8,997
Manufacturer 20	\$578,816	\$578,816	\$6,992	\$6,992
Manufacturer 21	\$887,344	\$887,344	\$6,638	\$640
Manufacturer 22	\$4,948	\$4,948	\$3,561	\$3,539
Manufacturer 23	\$369,532	\$369,532	\$2,316	\$2,316
Manufacturer 24	\$6,553,467	\$6,553,467	\$1,216	\$1,216
Manufacturer 25	\$7,089	\$7,089	\$1,002	\$1,260
Manufacturer 26	\$7,450	\$7,450	\$982	\$982
Manufacturer 27	\$10,825	\$10,825	\$905	\$905
Manufacturer 28	\$7,402	\$7,402	\$824	\$824
Manufacturer 29	\$2,976	\$2,976	\$237	\$237
Manufacturer 30	\$577,243	\$577,243	\$175	\$27
Manufacturer 31	\$373	\$373	\$113	\$113
Manufacturer 33	\$2,847	\$2,847	\$82	\$82
Manufacturer 34	\$27,304	\$27,304	\$66	\$66
Manufacturer 35	\$372,064	\$372,064	\$64	\$64
Manufacturer 36	\$42	\$42	\$5	\$5
Manufacturer 37	\$1,549,263	\$1,549,263	-	-

Manufacturer 38	\$840,816	\$840,816	-	-
Manufacturer 39	\$482,689	\$482,689	-	-
Manufacturer 40	\$463,291	\$463,291	-	-
Manufacturer 41	\$445,183	\$445,183	-	-
Manufacturer 42	\$440,530	\$440,530	-	-
Manufacturer 43	\$346,989	\$346,989	-	-
Manufacturer 44	\$318,803	\$318,803	-	-
Manufacturer 45	\$312,683	\$312,683	-	-
Manufacturer 46	\$283,257	\$283,257	-	-
Manufacturer 47	\$249,553	\$249,553	-	-
Manufacturer 48	\$244,281	\$244,281	-	-
Manufacturer 49	\$217,348	\$217,348	-	-
Manufacturer 50	\$137,474	\$137,474	-	-
Manufacturer 51	\$127,304	\$127,304	-	-
Manufacturer 52	\$118,738	\$118,738	-	-
Manufacturer 53	\$111,043	\$111,043	-	-
Manufacturer 54	\$107,776	\$107,776	-	-
Manufacturer 55	\$105,037	\$105,037	-	-
Manufacturer 56	\$101,498	\$101,498	-	-
Manufacturer 57	\$98,206	\$98,206	-	-
Manufacturer 58	\$85,767	\$85,767	-	-
Manufacturer 59	\$79,255	\$79,255	-	-
Manufacturer 60	\$72,905	\$72,905	-	-
Manufacturer 61	\$70,598	\$70,598	-	-
Manufacturer 62	\$54,725	\$54,725	-	-
Manufacturer 63	\$41,873	\$41,873	-	-
Manufacturer 64	\$41,448	\$41,448	-	-
Manufacturer 65	\$39,618	\$39,618	-	-
Manufacturer 65	\$38,498	\$38,498	-	-
Manufacturer 67	\$35,955	\$35,955	-	-
Manufacturer 68	\$34,753	\$34,753	-	-
Manufacturer 69	\$33,482	\$33,482	-	-
Manufacturer 70	\$32,951	\$32,951	-	-
Manufacturer 71	\$32,018	\$32,018	-	-
Manufacturer 72	\$26,921	\$26,921	-	-
Manufacturer 73	\$26,863	\$26,863	-	-
Manufacturer 74	\$24,331	\$24,331	-	-
Manufacturer 75	\$22,266	\$22,266	-	-
Manufacturer 76	\$19,545	\$19,545	-	-
Manufacturer 77	\$19,354	\$19,354	-	-
Manufacturer 78	\$17,726	\$17,726	-	-
Manufacturer 79	\$10,979	\$10,979	-	-

Manufacturer 80	\$9,705	\$9,705	-	-
Manufacturer 81	\$7,363	\$7,363	-	-
Manufacturer 82	\$7,220	\$7,220	-	-
Manufacturer 83	\$6,135	\$6,135	-	-
Manufacturer 84	\$6,058	\$6,058	-	-
Manufacturer 85	\$5,891	\$5,891	-	-
Manufacturer 86	\$5,306	\$5,306	-	-
Manufacturer 87	\$3,254	\$3,254	-	-
Manufacturer 88	\$2,867	\$2,867	-	-
Manufacturer 89	\$2,814	\$2,814	-	-
Manufacturer 90	\$2,538	\$2,538	-	-
Manufacturer 91	\$2,265	\$2,265	-	-
Manufacturer 92	\$2,170	\$2,170	-	-
Manufacturer 93	\$1,710	\$1,710	-	-
Manufacturer 94	\$1,653	\$1,653	-	-
Manufacturer 95	\$1,553	\$1,553	-	-
Manufacturer 96	\$1,380	\$1,380	-	-
Manufacturer 97	\$1,314	\$1,314	-	-
Manufacturer 98	\$1,258	\$1,258	-	-
Manufacturer 99	\$1,237	\$1,237	-	-
Manufacturer 100	\$1,150	\$1,150	-	-
Manufacturer 101	\$876	\$876	-	-
Manufacturer 102	\$440	\$440	-	-
Manufacturer 103	\$247	\$247	-	-
Manufacturer 104	\$72	\$72	-	-
Manufacturer 105	\$10	\$10	-	-
Manufacturer 106	\$6	\$6	-	-
Manufacturer 107	\$1	\$1	-	-
Manufacturer 108	-	-	-	-
Manufacturer 109	-	-	-	-
Manufacturer 110	-	-	-	-
Manufacturer 111	-	-	-	-
Manufacturer 112	-	-	-	-
Manufacturer 113	-	-	-	-
Manufacturer 114	-	-	-	-
Manufacturer 115	-	-	-	-
Manufacturer 116	-	-	-	-
Manufacturer 117	-	-	-	-
Manufacturer 118	-	-	-	-
Manufacturer 119	-	-	-	-
Manufacturer 120	-	-	-	-
Manufacturer 121	-	-	-	-

Manufacturer 122	-	-	-	-
Manufacturer 123	-	-	-	-
Manufacturer 124	-	-	-	-
Manufacturer 125	-	-	-	-
Manufacturer 126	-	-	-	-
Manufacturer 127	-	-	-	-
Manufacturer 128	-	-	-	-
Manufacturer 129	-	-	-	-
Manufacturer 130	-	-	-	-
Manufacturer 131	-	-	-	-
Manufacturer 132	-	-	-	-
Manufacturer 133	-	-	-	-
Manufacturer 134	-	-	-	-
Manufacturer 135	-	-	-	-
Manufacturer 136	-	-	-	-
Manufacturer 137	-	-	-	-
Manufacturer 138	-	-	-	-
Manufacturer 139	-	-	-	-
Manufacturer 140	-	-	-	-
Manufacturer 141	-	-	-	-
Manufacturer 142	-	-	-	-
Manufacturer 143	-	-	-	-
Manufacturer 144	-	-	-	-
Manufacturer 145	-	-	-	-
Manufacturer 146	-	-	-	-
Manufacturer 147	-	-	-	-
Manufacturer 148	-	-	-	-
Manufacturer 149	-	-	-	-
Manufacturer 150	-	-	-	-
Manufacturer 150	-	-	-	-
Manufacturer 151	-	-	-	-
Manufacturer 152	-	-	-	-
Manufacturer 153	-	-	-	-
Manufacturer 154	-	-	-	-
Manufacturer 155	-	-	-	-
Manufacturer 156	-	-	-	-
Manufacturer 157	-	-	-	-
Manufacturer 158	-	-	-	-
Manufacturer 159	-	-	-	-
Manufacturer 160	-	-	-	-
Manufacturer 161	-	-	-	-
Manufacturer 162	-	-	-	-



Manufacturer 163	-	-	-	-
Manufacturer 164	-	-	-	-
Manufacturer 165	-	-	-	-
Manufacturer 166	-	-	-	-
Manufacturer 167	-	-	-	-
Manufacturer 168	-	-	-	-
Manufacturer 169	-	-	-	-
Manufacturer 170	-	-	-	-
Manufacturer 171	-	-	-	-
Manufacturer 172	-	-	-	-
Manufacturer 173	-	-	-	-
Manufacturer 174	-	-	-	-
Manufacturer 175	-	-	-	-
Manufacturer 176	-	-	-	-
Manufacturer 177	-	-	-	-
Manufacturer 178	-	-	-	-
Manufacturer 179	-	-	-	-
Manufacturer 180	-	-	-	-
Manufacturer 181	-	-	-	-
Manufacturer 182	-	-	-	-

In addition to the collections listed in Table 3, during CY 2023 the State received \$22,285.98 in supplemental rebate payments from manufacturers without an active SRA in CY 2023. These payments are the result of supplemental rebate liabilities incurred by the manufacturer prior to calendar year 2023.

The next two tables provide additional information as required by Senate Bill 378 (2019). Table 4 below provides the values and total amounts of dispensing fees paid by DHCFP to pharmacies.

Table 4 Column Definitions:

- Retail 30 Days – Dispensing fee cost for 0–60-day supplies at a retail location
- Retail 90-100 Days – Dispensing fee cost for 90–100-day supplies at a retail location
- Mail Order – Dispensing fee cost for mail order pharmacies
- Specialty – Dispensing fees cost for specialty pharmacies

**Table 4**

Dispensing Fees during CY 2023				
Type of Dispensing Fee:	Retail 30 Days	Retail 90-100 Days	Mail Order	Specialty
Dispensing Fee	\$0.09	\$0.18	\$0.00	\$0.03
Totals	\$106,028.85	\$4,880.39	\$0.00	\$151.20
Grand Total	\$111,060.44			

Table 5 below provides a summary of measures employed by the pharmacy benefit manager contracted by DHCFP to control outpatient prescription drug costs.

Table 5 Row Definitions:

- Utilization Management – Measures to control use of pharmacy services for medical necessity and appropriateness to provide efficacious and cost-effective medications. Examples of utilization management include but not limited to prior authorization, step therapy, and quantity limits.
- Prior Authorization – Is a prospective review for an approval for the use of a medication.
- Step Therapy – Is a utilization management program that requires a patient to try a lower cost medication before stepping up to a similar-acting more expensive medication.
- Quantity limits – Limits medication use to the maximum dose of a medication.
- Pharmacy Networks – Is a group of pharmacies contracted with the payer where patients can fill medications.
- Preferred Drug List – Is a list of preferred medications that requires a patient to try the preferred medication before using a non-preferred medication.
- Prospective Drug Utilization Review (ProDUR) Total Cost Avoidance – Total amount of dollars that were avoided due to ProDUR activities which is an automated, structured, ongoing review of prescribing, dispensing and use of medications.

**Table 5**

Measures to Control Costs during CY 2023		
<b>Utilization Management</b>	<b>Prior Authorization</b>	Yes
	<b>Step Therapy</b>	Yes
	<b>Quantity Limits</b>	Yes
<b>Pharmacy Networks</b>		Yes
<b>Preferred Drug List</b>		Yes
<b>ProDUR Total Cost Avoidance</b>		\$39,114,071

**ATTACHMENT D**  
**SilverSummit Healthplan**

## **Silver Summit Supplemental Rebate Agreement Report Calendar Year 2023**

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid Drug Rebate Program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal Unit Rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter into separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists (PDL).

The Nevada Medicaid Supplemental Drug Rebate Program (NMSDRP) has been in effect since January 1, 2012. The SRAs are between the manufacturers and the Nevada Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP). Generally, the SRAs are in effect for one calendar year beginning on January 1<sup>st</sup> and terminating on December 31<sup>st</sup>. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new National Drug Codes released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31<sup>st</sup> end date such as a product moving to non-preferred status or to coincide with planned Silver State Scripts Board (SSSB) review.

During Calendar Year 2021, the rebates negotiated under the NMSDRP only applied to Medicaid fee-for-service (FFS) utilization. The other entities, authorized under Senate Bill 378 (2019) to participate in the Medicaid FFS PDL, did not elect to participate.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- "Percentage of WAC" - set percentage of the drug's published wholesale acquisition cost (WAC).
- "GNUP" (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
  - In the event a drug's WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
  - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer’s SRA with the Nevada Department of Health and Human Services, DHCFP.

Section F of the SRA provides confidentiality assurance that the State and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing related terms and conditions.

The Nevada Department of Health and Human Services, DHCFP had 38 SRAs in place that were in effect during Calendar Year 2021 (January 1, 2021 – December 31, 2021) (hereinafter referred to as CY 2021). Table 1 below summarizes the agreements.

Table 1 Row Definitions:

- Number of Contracts - The count of signed SRAs that were in force during some period within CY 2021.
- Number of Unique Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within CY 2021.
- Amount Plan Paid for Products During Contract Term - The amount The Nevada Department of Health and Human Services, DHCFP paid for all drug utilization subject to a manufacturer’s SRA during CY 2021.
  - Example: Drug “A” was subject to an SRA from 04/01/2021 to 12/31/2021 would include the amount paid for Drug “A” for claims paid from 04/01/2021 to 12/31/2021.
- Amount Medicaid Paid to Pharmacies/Providers for Products Under Contract – The amount Medicaid paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during calendar year 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2021 From manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.
  - Example: Manufacturer B was invoiced \$100.00 for supplemental rebates in November 2020 and remitted payment in January 2021. This column would include the payment since it was made during calendar year 2021.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products - The result of dividing Total Supplemental Rebates Invoiced **by** Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term.

**Table 1**

Summary of Supplemental Rebate Agreements during CY 2023	
<b>Number of Contracts</b>	218
<b>Number of Unique Manufacturers Under Contract</b>	182
<b>Amount Plan Paid for Products During Contract Term</b>	\$56,313,848
<b>Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term</b>	\$56,304,532
<b>Total Supplemental Rebates Invoiced</b>	\$1,716,091
<b>Total Supplemental Rebates Collected</b>	\$1,391,481

<b>Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products</b>	3.05%
--	-------

Table 2 below lists the SRAs in place during CY 2021. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA.
- Effective Date - The start date of the SRA.
- Term Date - The end date of the SRA.

**Table 2**

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
ABBOTT DIABETES CARE	1/1/2020	12/31/9999
ABBVIE INC	12/1/2020	12/31/9999
ACORDA THERAPEUTICS INC	1/1/2020	12/31/9999
AERIE	1/1/2020	12/31/9999
AKARX INC	9/1/2020	12/31/9999
AKEBIA THERAPEUTICS INC	1/1/2022	12/31/9999
AKORN, INC	1/1/2020	12/31/9999
ALCON LABORATORIES	1/1/2022	12/31/9999
ALEXION PHARMACEUTICALS INC	1/1/2020	12/31/9999
ALFASIGMA USA	1/1/2020	12/31/9999
ALK ABELLO INC	1/1/2020	12/31/9999
ALKERMES INC	4/1/2020	12/31/2025
ALLERGAN PHARM	4/1/2020	8/31/2025
ALMATICA	10/1/2020	12/31/9999
ALMIRALL LLC	1/1/2020	12/31/9999
ALVOGEN INC	7/1/2021	12/31/9999
AMAG PHARMACEUTICALS, INC	1/1/2020	12/31/9999
AMARIN	1/1/2020	12/31/9999
AMGEN	1/1/2023	12/31/9999
AMNEAL PHARMACEUTICALS LLC	1/1/2020	12/31/9999
ANI PHARMACEUTICALS	7/1/2021	12/31/9999
ANTARES PHARMA INC	1/1/2020	12/31/9999
ARBOR	1/1/2020	12/31/9999
ARKRAY USA INC	1/1/2020	12/31/9999
ASCEND THERAPEUTICS US, LLC	1/1/2020	3/31/2025
ASCENDIS PHARMA ENDOCRINOLOGY	11/1/2021	12/31/9999
ASCENSIA DIABETES CARE US INC	1/1/2020	12/31/9999
ASEGUA	1/1/2020	12/31/9999
ASSERTIO	1/1/2020	12/31/2023

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
ASTELLAS PHARMA US	1/1/2023	12/31/9999
ASTRAZENECA	4/1/2020	12/31/9999
AVANIR PHARMACEUTICALS	1/1/2020	12/31/2024
AVION PHARMACEUTICALS	1/1/2020	12/31/9999
BANNER LIFE SCIENCES	10/1/2020	12/31/9999
BAUSCH & LOMB	10/1/2021	12/31/9999
BAUSCH HEALTH US LLC	1/1/2020	12/31/9999
BAYER	1/1/2020	12/31/9999
BIODELIVERY SCIENCES INT	7/1/2019	12/31/9999
BIOFRONTERA INC	1/1/2020	2/28/2026
BIOGEN	1/1/2020	12/31/9999
BIOHAVEN PHARMACEUTICALS	1/1/2023	12/31/9999
BIOVENTUS LLC	1/1/2020	12/31/9999
BOEHRINGER INGELHEIM	4/1/2020	12/31/9999
BRISTOL-MYERS SQUIBB	4/1/2020	12/31/9999
CATALYST PHARMACEUTICALS	9/1/2023	12/31/9999
CEQR CORPORATION	1/1/2021	12/31/9999
CHIESI USA	1/1/2020	12/31/9999
CLARUS THERAPEUTICS	7/1/2021	12/31/9999
CLOVIS ONCOLOGY INC	1/1/2020	12/31/2023
COHERUS BIOSCIENCES	1/1/2020	8/31/2023
COLLEGIUM PHARMACEUTICALS	7/1/2019	12/31/9999
CORIUM LLC	7/1/2022	12/31/9999
COVIS PHARMA	7/1/2020	12/31/9999
CSL BEHRING LLC	4/1/2020	12/31/9999
CUMBERLAND PHARMACEUTICALS	1/1/2020	12/31/9999
CURRAX PHARMACEUTICALS LLC	1/1/2020	12/31/9999
CYCLE PHARMACEUTICALS	1/1/2020	12/31/9999
DEXCOM	1/1/2020	12/31/9999
DIGESTIVE CARE	1/1/2020	12/31/9999
DUCHESNAY USA, INC	1/1/2020	12/31/9999
EISAI INC	1/1/2020	12/31/9999
ELI LILLY & COMPANY	5/1/2020	12/31/2025
EMBECTA CORP	1/1/2020	12/31/9999
EMD SERONO	1/1/2022	12/31/2026
EMERGENT DEVICES	1/1/2021	12/31/9999
EMMAUS MEDICAL INC	1/1/2023	12/31/9999
ENDO PHARMACEUTICAL SOLUTIONS	7/1/2021	12/31/9999
EPI HEALTH LLC	1/1/2021	1/31/2024
ESPERION THERAPEUTICS	4/1/2020	12/31/2025

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
EXELIXIS INC	1/1/2020	12/31/9999
EXELTIS USA DERMATOLOGY	1/1/2020	12/31/9999
EYEVANCE	1/1/2020	12/31/2024
FERRING	1/1/2020	12/31/9999
FIDIA PHARMA USA INC	1/1/2020	8/31/2024
FRESENIUS KABI	7/1/2021	12/31/9999
FRESENIUS USA	1/1/2020	12/31/2024
GALDERMA	1/1/2021	12/31/9999
GENENTECH	1/1/2020	12/31/2025
GILEAD SCIENCES INC	7/1/2020	12/31/9999
GREENWICH BIOSCIENCES	1/1/2020	12/31/9999
GREER LABORATORIES, INC	1/1/2020	8/31/2026
GRIFOLS USA, LLC	1/1/2020	12/31/9999
H2 PHARMA	10/1/2023	12/31/9999
HARROW EYE	7/1/2023	12/31/9999
HEMA BIOLOGICS	1/1/2022	12/31/9999
HIKMA AMERICAS	1/1/2020	12/31/9999
HIKMA PHARMACEUTICALS	2/1/2023	12/31/9999
HORIZON MEDICINES LLC	1/1/2020	12/31/9999
HTL-STREFA	4/1/2021	12/31/9999
IMPEL PHARMACEUTICALS	10/1/2021	12/31/9999
INDIVIOR INC	7/1/2019	12/31/2024
INSULET	1/1/2020	12/31/9999
INTUITY MEDICAL	10/1/2021	12/31/9999
IPSEN BIOPHARMACEUTICALS INC	1/1/2020	12/31/9999
IRONSHORE	1/1/2020	12/31/9999
JAZZ	4/1/2020	12/31/2025
JOHNSON and JOHNSON	1/1/2023	12/31/9999
JOURNEY MEDICAL	9/1/2020	12/31/9999
KALA PHARMACEUTICALS INC	1/1/2020	12/31/2023
KALEO, INC	1/1/2022	12/31/9999
KOWA PHARMACEUTICALS	1/1/2022	12/31/9999
KYOWA KIRIN	1/1/2020	12/31/9999
LEO PHARMA, INC	1/1/2020	12/31/9999
LIFESCAN	1/1/2020	12/31/2025
LUPIN PHARMACEUTICALS, INC	7/1/2021	12/31/9999
MALLINCKRODT	10/1/2019	12/31/9999
MANNKIND CORPORATION	1/1/2020	12/31/9999
MAYNE PHARMA	1/1/2020	12/31/9999
MEDEXUS PHARMA	1/1/2020	12/31/2023



Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
MEDUNIK USA	7/1/2022	12/31/9999
MELINTA THERAPEUTICS LLC	1/1/2020	12/31/9999
MERCK & CO, INC	10/1/2021	12/31/9999
METUCHEN	1/1/2020	12/31/9999
MILLENNIUM PHARMACEUTICALS	1/1/2021	12/31/9999
MILLICENT	1/1/2020	12/31/9999
MINIMED DISTRIBUTION CORP	1/1/2020	12/31/9999
MISSION	1/1/2020	12/31/9999
MYLAN PHARMACEUTICALS INC	4/1/2020	12/31/9999
MYOVANT	6/1/2022	12/31/9999
NABRIVA	1/1/2020	12/31/9999
NEOS THERAPEUTICS LP	1/1/2020	4/30/2023
NESTLE HEALTH SCIENCE	1/1/2021	12/31/9999
NEURELIS	10/1/2020	12/31/9999
NEUROCRINE BIOSCIENCES INC	1/1/2020	12/31/9999
NODEN PHARMA USA	1/1/2020	12/31/9999
NOVARTIS	7/1/2020	12/31/9999
NOVARTIS GENE THERAPY	1/1/2023	12/31/9999
NOVEN THERAPEUTICS LLC	1/1/2021	12/31/9999
NOVO NORDISK	4/1/2020	12/31/9999
OCTAPHARMA USA	7/1/2021	12/31/9999
OPKO PHARMACEUTICALS LLC	1/1/2020	12/31/9999
OPTINOSE US, INC	1/1/2020	12/31/9999
OREXO	7/1/2019	12/31/9999
ORGANON	12/1/2022	12/31/9999
OTSUKA	1/1/2021	12/31/9999
OYSTER POINT PHARMA INC	7/1/2022	12/31/9999
PADAGIS US LLC	1/1/2020	12/31/9999
PARATEK PHARMACEUTICALS, INC	1/1/2020	12/31/9999
PARI RESPIRATORY	1/1/2020	12/31/9999
PFIZER US PHARM	7/1/2021	12/31/9999
PHARMING HEALTHCARE INC	1/1/2020	12/31/9999
PIERRE FABRE PHARMA INC	1/1/2020	12/31/9999
PURDUE PHARMA	10/1/2019	12/31/9999
RADIUS HEALTH INC	1/1/2020	12/31/9999
RB HEALTH (US) LLC	1/1/2020	12/31/9999
RECORDATI RARE DISEASES	1/1/2023	12/31/2025
REDHILL BIOPHARMA	10/1/2020	12/31/9999
REGENERON PHARMACEUTICALS INC	10/1/2020	8/31/2024
RESILIA PHARMACEUTICALS	10/1/2021	12/31/2024

Supplemental Rebate Agreements during CY 2023		
Manufacturer Name	Effective Date	Term Date
RIGEL	1/1/2022	12/31/9999
ROCHE DIABETES CARE, INC	1/1/2020	12/31/9999
SANDOZ INC	4/1/2020	12/31/9999
SANOFI - AVENTIS	1/1/2023	12/31/9999
SCILEX PHARMACEUTICALS INC	7/1/2019	12/31/9999
SEBELA PHARMACEUTICALS INC	1/1/2021	12/31/9999
SECURA BIO	1/1/2021	12/31/9999
SHIONOGI & COMPANY, INC	1/1/2020	12/31/2024
SK LIFE SCIENCE	4/1/2020	12/31/9999
SOBI INC	1/1/2020	12/31/9999
SUN PHARMA INDUSTRIES INC	1/1/2021	12/31/9999
SUNOVION	1/1/2020	12/31/9999
SUPERNUS PHARMACEUTICALS, INC	1/1/2020	12/31/9999
TAKEDA	1/1/2023	12/31/9999
TEVA	1/1/2023	12/31/9999
THEA PHARMA INC	7/1/2022	12/31/9999
THERAPEUTICSMD INC	1/1/2023	12/31/9999
TOLMAR, INC	10/1/2020	12/31/9999
TRAVERE THERAPEUTICS INC	1/1/2020	12/31/9999
TRIS PHARMA	1/1/2020	11/30/2024
TRIVIDIA HEALTH	1/1/2020	12/31/9999
UCB INC	1/1/2022	12/31/2025
UPSHER-SMITH	1/1/2020	12/31/9999
UROVANT	8/1/2021	12/31/9999
VALINOR PHARMA	11/1/2023	12/31/9999
VELOXIS PHARMACEUTICALS	1/1/2020	12/31/9999
VERTICAL PHARMACEUTICALS	1/1/2020	12/31/9999
VIFOR PHARMA, INC	1/1/2020	3/31/2025
VISTAPHARM	10/1/2021	12/31/9999
VIVUS	1/1/2020	12/31/9999
WOMENS CHOICE PHARMACEUTICALS	1/1/2020	12/31/9999
XERIS	3/1/2020	12/31/9999
ZIMMER US, INC	1/1/2020	12/31/9999

Table 3 below provides the value for each individual SRA. Table 3 is sorted by descending contract value. Table

3 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted within the SRA.
- Amount Plan Paid for Products During Contract Term - The amount paid for all drugs subject to a manufacturer's SRA during CY 2021.

- Example: Drug “A” was subject to an SRA from 06/01/2019 to 03/31/2021. This column would include the amount paid for Drug “A” for claims paid from 01/01/2021 to 03/31/2021.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2021 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.

**Table 3**

Supplemental Rebate Agreements during CY 2022				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
Manufacturer 1	\$627,758	\$627,758	\$533,366	\$531,282
Manufacturer 2	\$4,791,521	\$4,791,521	\$351,047	\$76,672
Manufacturer 3	\$1,570,654	\$1,572,057	\$188,908	\$188,590
Manufacturer 4	\$5,717,450	\$5,717,450	\$160,871	\$141,162
Manufacturer 5	\$528,628	\$528,628	\$107,200	\$89,120
Manufacturer 6	\$1,331,721	\$1,331,720	\$81,800	\$81,799
Manufacturer 7	\$206,564	\$206,564	\$60,353	\$59,016
Manufacturer 8	\$129,995	\$129,995	\$49,465	\$49,260
Manufacturer 9	\$1,379,828	\$1,379,828	\$33,108	\$31,391
Manufacturer 10	\$3,750,786	\$3,750,786	\$28,463	\$27,580
Manufacturer 11	\$1,691,578	\$1,691,578	\$27,125	\$27,123
Manufacturer 12	\$190,939	\$190,939	\$16,289	\$15,516
Manufacturer 13	\$336,802	\$336,785	\$9,925	\$9,925
Manufacturer 14	\$348,393	\$348,393	\$9,619	\$9,233
Manufacturer 15	\$395,769	\$395,769	\$9,517	\$9,517
Manufacturer 16	\$3,582,376	\$3,582,376	\$9,495	\$9,437
Manufacturer 17	\$986,707	\$986,707	\$8,018	\$8,018
Manufacturer 18	\$766,350	\$761,140	\$5,614	\$3,253
Manufacturer 19	\$21,510	\$21,510	\$5,531	\$5,531
Manufacturer 20	\$16,999	\$16,999	\$3,891	\$3,881
Manufacturer 21	\$56,883	\$56,883	\$3,633	\$2,982
Manufacturer 22	\$9,610	\$9,610	\$3,276	\$2,634
Manufacturer 23	\$7,774	\$7,774	\$2,088	\$2,088
Manufacturer 24	\$12,085	\$12,085	\$1,637	\$1,637
Manufacturer 25	\$155,601	\$155,601	\$1,038	-
Manufacturer 26	\$218,836	\$218,836	\$1,001	\$996
Manufacturer 27	\$3,270	\$3,270	\$845	\$845
Manufacturer 28	\$20,830	\$20,830	\$822	\$822
Manufacturer 29	\$510,604	\$510,604	\$732	\$732
Manufacturer 30	\$3,389	\$3,389	\$569	\$569
Manufacturer 31	\$4,466	\$4,466	\$223	\$223
Manufacturer 32	\$250,367	\$250,367	\$199	\$199

Manufacturer 33	\$421	\$421	\$135	\$135
Manufacturer 34	\$543	\$543	\$119	\$119
Manufacturer 35	\$1,032	\$1,032	\$50	\$50
Manufacturer 36	\$218,836	\$218,836	\$41	\$41
Manufacturer 37	\$915	\$915	\$37	\$37
Manufacturer 38	\$2,127,623	\$2,127,623	\$31	\$59
Manufacturer 39	\$119	\$119	\$10	\$10
Manufacturer 40	\$57	\$57	\$6	\$6
Manufacturer 41	\$7,188	\$7,188	-\$5	(\$6)
Manufacturer 42	\$10,232,553	\$10,233,771	-	-
Manufacturer 43	\$1,845,169	\$1,845,169	-	-
Manufacturer 44	\$1,734,975	\$1,734,975	-	-
Manufacturer 45	\$1,661,129	\$1,661,129	-	-
Manufacturer 46	\$1,550,448	\$1,550,481	-	-
Manufacturer 47	\$858,633	\$858,633	-	-
Manufacturer 48	\$783,291	\$783,227	-	-
Manufacturer 49	\$548,518	\$548,518	-	-
Manufacturer 50	\$537,821	\$537,821	-	-
Manufacturer 51	\$366,075	\$366,075	-	-
Manufacturer 52	\$356,488	\$356,488	-	-
Manufacturer 53	\$336,283	\$336,283	-	-
Manufacturer 54	\$305,456	\$305,386	-	-
Manufacturer 55	\$288,362	\$288,362	-	-
Manufacturer 56	\$284,181	\$284,181	-	-
Manufacturer 57	\$224,586	\$224,586	-	-
Manufacturer 58	\$202,589	\$196,259	-	-
Manufacturer 59	\$181,429	\$181,429	-	-
Manufacturer 60	\$172,602	\$172,602	-	-
Manufacturer 61	\$161,060	\$161,060	-	-
Manufacturer 62	\$141,272	\$141,272	-	-
Manufacturer 63	\$130,955	\$130,955	-	-
Manufacturer 64	\$121,109	\$120,911	-	-
Manufacturer 65	\$97,564	\$97,564	-	-
Manufacturer 66	\$96,344	\$96,344	-	-
Manufacturer 67	\$92,388	\$92,388	-	-
Manufacturer 68	\$89,903	\$89,903	-	-
Manufacturer 69	\$89,317	\$89,317	-	-
Manufacturer 70	\$83,105	\$83,105	-	-
Manufacturer 71	\$79,952	\$79,952	-	-
Manufacturer 72	\$64,873	\$64,952	-	-
Manufacturer 73	\$50,479	\$50,479	-	-
Manufacturer 74	\$47,497	\$47,497	-	-
Manufacturer 75	\$45,851	\$45,851	-	-
Manufacturer 76	\$45,604	\$45,446	-	-
Manufacturer 77	\$41,454	\$41,454	-	-
Manufacturer 78	\$34,402	\$34,402	-	-
Manufacturer 79	\$32,997	\$32,997	-	-
Manufacturer 80	\$31,482	\$31,482	-	-
Manufacturer 81	\$27,372	\$27,372	-	-
Manufacturer 82	\$24,585	\$24,585	-	-

Manufacturer 83	\$21,206	\$21,206	-	-
Manufacturer 84	\$20,660	\$20,660	-	-
Manufacturer 85	\$17,585	\$17,585	-	-
Manufacturer 86	\$17,136	\$17,136	-	-
Manufacturer 87	\$14,853	\$14,853	-	-
Manufacturer 88	\$14,743	\$14,743	-	-
Manufacturer 89	\$14,067	\$14,067	-	-
Manufacturer 90	\$13,306	\$13,306	-	-
Manufacturer 91	\$12,783	\$12,783	-	-
Manufacturer 92	\$12,735	\$12,735	-	-
Manufacturer 93	\$7,776	\$7,776	-	-
Manufacturer 94	\$7,460	\$7,460	-	-
Manufacturer 95	\$6,084	\$6,084	-	-
Manufacturer 96	\$5,474	\$5,474	-	-
Manufacturer 97	\$5,313	\$5,313	-	-
Manufacturer 98	\$4,377	\$4,377	-	-
Manufacturer 99	\$4,366	\$4,366	-	-
Manufacturer 100	\$4,327	\$4,327	-	-
Manufacturer 101	\$4,023	\$4,023	-	-
Manufacturer 102	\$3,620	\$3,620	-	-
Manufacturer 103	\$2,961	\$2,961	-	-
Manufacturer 104	\$2,143	\$2,143	-	-
Manufacturer 105	\$1,820	\$1,820	-	-
Manufacturer 106	\$1,677	\$1,677	-	-
Manufacturer 107	\$1,665	\$1,665	-	-
Manufacturer 108	\$1,661	\$1,661	-	-
Manufacturer 109	\$1,553	\$1,553	-	-
Manufacturer 110	\$1,458	\$1,458	-	-
Manufacturer 111	\$1,205	\$1,205	-	-
Manufacturer 112	\$852	\$852	-	-
Manufacturer 113	\$544	\$544	-	-
Manufacturer 114	\$474	\$474	-	-
Manufacturer 115	\$269	\$269	-	-
Manufacturer 116	\$169	\$169	-	-
Manufacturer 117	\$162	\$162	-	-
Manufacturer 118	\$160	\$160	-	-
Manufacturer 119	\$137	\$137	-	-
Manufacturer 120	\$78	\$78	-	-
Manufacturer 121	\$37	\$37	-	-
Manufacturer 122	\$3	\$3	-	-
Manufacturer 123	-	-	-	-
Manufacturer 124	-	-	-	-
Manufacturer 125	-	-	-	-
Manufacturer 126	-	-	-	-
Manufacturer 127	-	-	-	-
Manufacturer 128	-	-	-	-
Manufacturer 129	-	-	-	-
Manufacturer 130	-	-	-	-
Manufacturer 131	-	-	-	-
Manufacturer 132	-	-	-	-

Manufacturer 133	-	-	-	-
Manufacturer 134	-	-	-	-
Manufacturer 135	-	-	-	-
Manufacturer 136	-	-	-	-
Manufacturer 137	-	-	-	-
Manufacturer 138	-	-	-	-
Manufacturer 139	-	-	-	-
Manufacturer 140	-	-	-	-
Manufacturer 141	-	-	-	-
Manufacturer 142	-	-	-	-
Manufacturer 143	-	-	-	-
Manufacturer 144	-	-	-	-
Manufacturer 145	-	-	-	-
Manufacturer 146	-	-	-	-
Manufacturer 147	-	-	-	-
Manufacturer 148	-	-	-	-
Manufacturer 149	-	-	-	-
Manufacturer 150	-	-	-	-
Manufacturer 151	-	-	-	-
Manufacturer 152	-	-	-	-
Manufacturer 153	-	-	-	-
Manufacturer 154	-	-	-	-
Manufacturer 155	-	-	-	-
Manufacturer 156	-	-	-	-
Manufacturer 157	-	-	-	-
Manufacturer 158	-	-	-	-
Manufacturer 159	-	-	-	-
Manufacturer 160	-	-	-	-
Manufacturer 161	-	-	-	-
Manufacturer 162	-	-	-	-
Manufacturer 163	-	-	-	-
Manufacturer 164	-	-	-	-
Manufacturer 165	-	-	-	-
Manufacturer 166	-	-	-	-
Manufacturer 167	-	-	-	-
Manufacturer 168	-	-	-	-
Manufacturer 169	-	-	-	-
Manufacturer 170	-	-	-	-
Manufacturer 171	-	-	-	-
Manufacturer 172	-	-	-	-
Manufacturer 173	-	-	-	-
Manufacturer 174	-	-	-	-
Manufacturer 175	-	-	-	-
Manufacturer 176	-	-	-	-
Manufacturer 177	-	-	-	-
Manufacturer 178	-	-	-	-
Manufacturer 179	-	-	-	-
Manufacturer 180	-	-	-	-
Manufacturer 181	-	-	-	-
Manufacturer 182	-	-	-	-

In addition to the collections listed in Table 3, during CY 2021 the State received \$22,285.98 in supplemental rebate payments from manufacturers without an active SRA in CY 2021. These payments are the result of supplemental rebate liabilities incurred by the manufacturer prior to calendar year 2021.

The next two tables provide additional information as required by Senate Bill 378 (2019). Table 4 below provides the values and total amounts of dispensing fees paid by DHCFP to pharmacies.

Table 4 Column Definitions:

- Retail 30 Days – Dispensing fee cost for 0–60-day supplies at a retail location
- Retail 90-100 Days – Dispensing fee cost for 90–100-day supplies at a retail location
- Mail Order – Dispensing fee cost for mail order pharmacies
- Specialty – Dispensing fees cost for specialty pharmacies

**Table 4**

<b>Dispensing Fees during CY 2023</b>				
Type of Dispensing Fee:	Retail 30 Days	Retail 90-100 Days	Mail Order	Specialty
Dispensing Fee	\$0.09	\$0.02	\$0.00	\$0.00
Totals	\$135,044.54	\$1,043.61	\$0.00	\$(102.33)
Grand Total	\$135,985.82			

Table 5 below provides a summary of measures employed by the pharmacy benefit manager contracted by DHCFP to control outpatient prescription drug costs.

Table 5 Row Definitions:

- Utilization Management – Measures to control use of pharmacy services for medical necessity and appropriateness to provide efficacious and cost-effective medications. Examples of utilization management include but not limited to prior authorization, step therapy, and quantity limits.
- Prior Authorization – Is a prospective review for an approval for the use of a medication.
- Step Therapy – Is a utilization management program that requires a patient to try a lower cost medication before stepping up to a similar-acting more expensive medication.
- Quantity limits – Limits medication use to the maximum dose of a medication.
- Pharmacy Networks – Is a group of pharmacies contracted with the payer where patients can fill medications.
- Preferred Drug List – Is a list of preferred medications that requires a patient to try the preferred medication before using a non-preferred medication.
- Prospective Drug Utilization Review (ProDUR) Total Cost Avoidance – Total amount of dollars that were avoided due to ProDUR activities which is an automated, structured, ongoing review of prescribing, dispensing and use of medications.

**Table 5**

<b>Measures to Control Costs during CY 2023</b>		
<b>Utilization Management</b>	<b>Prior Authorization</b>	Yes
	<b>Step Therapy</b>	No
	<b>Quantity Limits</b>	Yes
<b>Pharmacy Networks</b>		No
<b>Preferred Drug List</b>		Yes
<b>ProDUR Total Cost Avoidance</b>		104,234,713



**ATTACHMENT E**  
**Nevada Medicaid Fee-For-Service**

## **Nevada Medicaid Fee-For-Service Supplemental Rebate Agreement Report Calendar Year 2023**

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid Drug Rebate Program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal Unit Rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter into separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists (PDL).

The Nevada Medicaid Supplemental Drug Rebate Program (NMSDRP) has been in effect since January 1, 2012 with majority ending September 30, 2022. National Medicaid Pooling Initiative (NMPI) SRAs have been in effect since October 1, 2022. The NMSDRP SRAs were between the manufacturers and the Nevada Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP) and NMPI SRAs are between the manufacturers and Prime Therapeutics, LLC. Generally, the NMPI SRAs are in effect for 3 years beginning on April 1<sup>st</sup> and terminating on March 31<sup>st</sup>. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new National Drug Codes released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-March 31<sup>st</sup> end date such as a product moving to non-preferred status or to coincide with planned Silver State Scripts Board (SSSB) review.

During Calendar Year 2023, the rebates negotiated under NMPI only applied to Medicaid fee-for-service (FFS) utilization. The other entities, authorized under Nevada Revised Statutes (NRS) 422.4025 to participate in the Medicaid FFS PDL, did not elect to participate.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- "Percentage of WAC" - set percentage of the drug's published wholesale acquisition cost (WAC).
- "GNUP" (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
  - In the event a drug's WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.

- Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer’s SRA with the Nevada Department of Health and Human Services, DHCFP or with Prime Therapeutics, LLC.

Section F of the SRA provides confidentiality assurance that the State and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing related terms and conditions.

The Nevada Department of Health and Human Services, DHCFP had 81 SRAs through NMPI that were in effect during Calendar Year 2023 (January 1, 2023 – December 31, 2023) (hereinafter referred to as CY 2023). Table 1 below summarizes the agreements.

**Table 1 Row Definitions:**

- Number of Contracts - The count of signed SRAs that were in force during some period within CY 2023.
- Number of Unique Manufacturers Under Contract - The count of unique manufacturers with a signed SRA in force during some period within CY 2023.
- Amount Plan Paid for Products During Contract Term - The amount The Nevada Department of Health and Human Services, DHCFP paid for all drug utilization subject to a manufacturer’s SRA during CY 2023.
  - Example: Drug “A” was subject to an SRA from 04/01/2023 to 12/31/2023 would include the amount paid for Drug “A” for claims paid from 04/01/2023 to 12/31/2023.
- Amount Medicaid Paid to Pharmacies/Providers for Products Under Contract – The amount Medicaid paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2023.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2023 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2023 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.
  - Example: Manufacturer B was invoiced \$100.00 for supplemental rebates in November 2020 and remitted payment in January 2023. This column would include the payment since it was made during CY 2023.
- Supplemental Rebate Percentage of Drug Spend for Contracted Products - The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

**Table 1**

<b>Summary of Supplemental Rebate Agreements during CY 2023</b>	
<b>Number of Contracts</b>	81
<b>Number of Unique Manufacturers</b>	50
<b>Amount Plan Paid for Products During Contract Term</b>	\$189,802,698.59
<b>Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term</b>	\$189,802,698.59
<b>Total Supplemental Rebates Invoiced</b>	\$17,704,580.82
<b>Total Supplemental Rebates Collected</b>	\$17,846,037.74
<b>Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products</b>	9.33%

Tables 2 below list the SRAs in place during CY 2023. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA.
- Effective Date - The start date of the SRA.
- Term Date - The end date of the SRA.

**Table 2**

<b>NMPI Supplemental Rebate Agreements during 2023 (1/1/2023-12/31/2023)</b>		
<b>Manufacturer</b>	<b>NDC Effective Date</b>	<b>NDC Termination Date</b>
ABBVIE	10/1/2022	3/31/2023
ABBVIE	04/01/2023	03/31/2026
ACTELION	10/1/2022	3/31/2023
AERIE	10/1/2022	3/31/2023
AERIE	04/01/2023	03/31/2026
ALKERMES	10/1/2022	3/31/2023
ALKERMES	04/01/2023	03/31/2026
ALLERGAN	10/1/2022	3/31/2023
AMGEN	10/1/2022	3/31/2023
AMGEN	04/01/2023	03/31/2026
ASEGUA	10/1/2022	3/31/2023
ASEGUA	04/01/2023	03/31/2026
ASTRAZENECA PHARMACEUTICALS	10/1/2022	3/31/2023
ASTRAZENECA PHARMACEUTICALS	04/01/2023	03/31/2026
BAXALTA US	10/1/2022	3/31/2023
BAYER HEALTHCARE	10/1/2022	3/31/2023
BIOHAVEN	10/1/2022	3/31/2023
BOEHRINGER INGELHEIM	10/1/2022	3/31/2023

BOEHRINGER INGELHEIM	04/01/2023	03/31/2026
BRAEBURN INC.	12/28/2023	3/31/2026
BRISTOL-MYERS SQUIBB	10/1/2022	3/31/2023
BRISTOL-MYERS SQUIBB	04/01/2023	03/31/2026
CATALYST	04/01/2023	03/31/2026
CHIESI	10/1/2022	3/31/2023
CHIESI	04/01/2023	03/31/2026
DUCHESNAY	10/1/2022	3/31/2023
DUCHESNAY	04/01/2023	03/31/2026
EISAI	10/1/2022	3/31/2023
ELI LILLY	10/1/2022	3/31/2023
ELI LILLY	04/01/2023	03/31/2026
EMMAUS	04/06/2023	03/31/2026
EXELTIS USA	04/01/2023	03/31/2026
GENENTECH	10/1/2022	3/31/2023
GENENTECH	04/01/2023	03/31/2026
GENZYME	10/1/2022	3/31/2023
GENZYME	04/01/2023	04/26/2023
GILEAD	10/1/2022	3/31/2023
GILEAD	04/01/2023	07/05/2023
GLAXOSMITHKLINE	04/01/2023	03/31/2026
HIKMA SPECIALTY	10/1/2022	3/31/2023
HIKMA SPECIALTY	04/01/2023	03/31/2026
INDIVIOR	10/1/2022	3/31/2023
INDIVIOR	04/01/2023	03/31/2026
JANSSEN PHARMACEUTICALS	10/1/2022	3/31/2023
JANSSEN PHARMACEUTICALS	04/01/2023	03/31/2026
MEDECOR	04/01/2023	03/31/2026
MEDUNIK	04/06/2023	03/31/2026
MYLAN SPECIALTY	04/01/2023	03/31/2026
NESTLE	10/1/2022	3/31/2023
NESTLE	04/01/2023	03/31/2026
NEURELIS	10/1/2022	3/31/2023
NEURELIS	04/01/2023	03/31/2026
NEUROCRINE	10/1/2022	3/31/2023
NEUROCRINE	04/01/2023	03/31/2026
NOVARTIS	10/1/2022	3/31/2023
NOVARTIS	04/01/2023	03/31/2026
NOVO NORDISK	10/1/2022	3/31/2023
NOVO NORDISK	04/01/2023	03/31/2026
OTSUKA	10/1/2022	3/31/2023

OTSUKA	04/01/2023	03/31/2026
PARAPRO	10/1/2022	3/31/2023
PARAPRO	04/01/2023	03/31/2026
PARI RESPIRATORY	10/1/2022	3/31/2023
PARI RESPIRATORY	04/01/2023	03/31/2026
PFIZER	10/1/2022	3/31/2023
PFIZER	04/01/2023	03/31/2026
SANOFI AVENTIS	10/1/2022	3/31/2023
SANOFI AVENTIS	04/01/2023	03/31/2026
SHIRE	10/1/2022	3/31/2023
SUNOVION	10/1/2022	3/31/2023
SUNOVION	04/01/2023	04/26/2023
TAKEDA	10/1/2022	3/31/2023
TEVA NEUROSCIENCE	10/1/2022	3/31/2023
TEVA PHARMACEUTICALS	10/1/2022	3/31/2023
TEVA PHARMACEUTICALS	04/01/2023	03/31/2026
UCB	10/1/2022	3/31/2023
UCB	04/01/2023	03/31/2026
VIVUS, INC.	10/1/2022	3/31/2023
XERIS	12/29/2022	3/31/2023
XERIS	04/01/2023	03/31/2026
ZEALAND	10/1/2022	3/31/2023

Table 3 below provides the value for each individual SRA.

Table 3 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted within the SRA.
- Amount Plan Paid for Products During Contract Term - The amount paid for all drugs subject to a manufacturer's SRA during CY 2023.
  - Example: Drug "A" was subject to an SRA from 06/01/2022 to 03/31/2023. This column would include the amount paid for Drug "A" for claims paid from 01/01/2023 to 03/31/2023.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2023 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2023 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.

**Table 3**

<b>Supplemental Rebate Agreements during CY 2023</b>				
<b>Manufacturer Name</b>	<b>Amount Plan Paid for Products During Contract Term</b>	<b>Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term</b>	<b>Total Supplemental Rebates Invoiced</b>	<b>Total Supplemental Rebates Collected</b>
Manufacturer 1	\$14,423,918.82	\$14,423,918.82	\$6,099,393.36	\$6,190,263.63
Manufacturer 2	\$16,477,044.00	\$16,477,044.00	\$2,332,832.98	\$2,325,845.58
Manufacturer 3	\$14,525,168.70	\$14,525,168.70	\$2,304,415.37	\$2,301,615.24
Manufacturer 4	\$9,041,271.67	\$9,041,271.67	\$1,282,140.99	\$1,289,502.16
Manufacturer 5	\$2,738,724.50	\$2,738,724.50	\$887,472.23	\$895,229.35
Manufacturer 6	\$3,626,837.47	\$3,626,837.47	\$798,942.25	\$798,942.25
Manufacturer 7	\$4,138,992.64	\$4,138,992.64	\$527,063.44	\$527,063.43
Manufacturer 8	\$27,507,600.96	\$27,507,600.96	\$632,781.32	\$432,002.36
Manufacturer 9	\$1,797,870.61	\$1,797,870.61	\$395,693.43	\$395,693.46
Manufacturer 10	\$11,432,614.47	\$11,432,614.47	\$4,845.71	\$378,943.29
Manufacturer 11	\$8,825,852.31	\$8,825,852.31	\$424,085.68	\$368,387.68
Manufacturer 12	\$11,717,984.83	\$11,717,984.83	\$305,017.58	\$305,962.85
Manufacturer 13	\$1,965,922.69	\$1,965,922.69	\$214,098.24	\$214,098.47
Manufacturer 14	\$10,110,385.74	\$10,110,385.74	\$198,435.71	\$201,083.57
Manufacturer 15	\$991,354.07	\$991,354.07	\$179,367.42	\$179,367.48
Manufacturer 16	\$663,334.52	\$663,334.52	\$156,232.54	\$156,232.54
Manufacturer 17	\$3,122,094.42	\$3,122,094.42	\$126,348.30	\$138,250.42
Manufacturer 18	\$339,224.48	\$339,224.48	\$137,648.01	\$134,972.92
Manufacturer 19	\$5,577,063.73	\$5,577,063.73	\$87,201.48	\$78,195.39
Manufacturer 20	\$334,205.96	\$334,205.96	\$33,707.86	\$33,707.86
Manufacturer 21	\$201,035.62	\$201,035.62	\$22,700.03	\$22,697.71
Manufacturer 22	\$105,835.54	\$105,835.54	\$21,989.97	\$19,805.75
Manufacturer 23	\$64,560.78	\$64,560.78	\$16,919.04	\$16,918.63
Manufacturer 24	\$484,350.87	\$484,350.87	\$15,108.87	\$13,832.76
Manufacturer 25	\$3,501,810.19	\$3,501,810.19	\$13,222.12	\$13,166.06
Manufacturer 26	\$9,556,079.37	\$9,556,079.37	\$11,021.22	\$12,411.51
Manufacturer 27	\$54,122.04	\$54,122.04	\$9,801.67	\$4,370.53
Manufacturer 28	\$6,276.50	\$6,276.50	\$2,383.52	\$2,383.65
Manufacturer 29	\$2,291,606.14	\$2,291,606.14	\$2,117.15	\$2,117.16
Manufacturer 30	\$2,299,509.46	\$2,299,509.46	\$2,067.75	\$2,115.50
Manufacturer 31	\$10,009.52	\$10,009.52	\$1,760.78	\$1,760.78
Manufacturer 32	\$6,455,582.37	\$6,455,582.37	\$1,366.57	\$1,365.73
Manufacturer 33	\$25,177.46	\$25,177.46	\$890.14	\$1,315.35

Manufacturer 34	\$3,502.21	\$3,502.21	\$1,054.82	\$1,054.82
Manufacturer 35	\$205,052.79	\$205,052.79	\$4,358.46	\$0.00
Manufacturer 36	\$188,229.60	\$188,229.60	\$4,736.75	\$0.00
Manufacturer 37	\$15.15	\$15.15	\$0.00	\$0.00
Manufacturer 38	\$826,771.45	\$826,771.45	\$0.00	\$0.00
Manufacturer 39	\$2,950,948.15	\$2,950,948.15	\$63,648.40	\$0.00
Manufacturer 40	\$6,230,625.65	\$6,230,625.65	\$341,896.52	\$341,896.52
Manufacturer 41	\$1,438,743.14	\$1,438,743.14	\$13,073.52	\$13,231.91
Manufacturer 42	\$876,444.19	\$876,444.19	\$0.00	\$0.00
Manufacturer 43	\$662,837.37	\$662,837.37	\$19,781.49	\$22,696.21
Manufacturer 44	\$470,382.10	\$470,382.10	\$0.00	\$0.00
Manufacturer 45	\$447,535.09	\$447,535.09	\$0.00	\$0.00
Manufacturer 46	\$398,690.85	\$398,690.85	\$6,475.13	\$7,537.23
Manufacturer 47	\$346,391.35	\$346,391.35	\$0.00	\$0.00
Manufacturer 48	\$321,722.50	\$321,722.50	\$0.00	\$0.00
Manufacturer 49	\$17,011.68	\$17,011.68	\$0.00	\$0.00
Manufacturer 50	\$4,372.87	\$4,372.87	\$483.00	\$0.00

The next two tables provide additional information as required by NRS 422.4053 (3)(b). Table 4 below provides the values and total amounts of dispensing fees paid by DHCFP to pharmacies.

Table 4 Column Definitions:

- Retail 30 Days – Dispensing fee cost for 0–60-day supplies at a retail location
- Retail 60-100 Days – Dispensing fee cost for 60–100-day supplies at a retail location
- Mail Order – Dispensing fee cost for mail order pharmacies
- Specialty – Dispensing fees cost for specialty pharmacies.

**Table 4**

<b>Dispensing Fees during CY 2023</b>				
<b>Type of Dispensing Fee:</b>	<b>Retail 30 Days</b>	<b>Retail 60-100 Days</b>	<b>Mail Order</b>	<b>Specialty</b>
<b>Dispensing Fee</b>	\$10.17	\$10.17	10.17	10.17
<b>Totals</b>	\$16,553,305.87	\$2,300,642.37	\$1,688.22	\$101,140.65
<b>Grand Total</b>	\$18,956,777.11			

Table 5 below provides a summary of measures employed by the pharmacy benefit manager contracted by DHCFP to control outpatient prescription drug costs.

Table 5 Row Definitions:

- Utilization Management – Measures to control use of pharmacy services for medical necessity and appropriateness to provide efficacious and cost-effective medications. Examples of utilization management include but not limited to prior authorization, step



therapy, and quantity limits.

- Prior Authorization – Is a prospective review for an approval for the use of a medication.
- Step Therapy – Is a utilization management program that requires a patient to try a lower cost medication before stepping up to a similar-acting more expensive medication.
- Quantity limits – Limits medication use to the maximum dose of a medication.
- Pharmacy Networks – Is a group of pharmacies contracted with the payer where patients can fill medications.
- Preferred Drug List – Is a list of preferred medications that requires a patient to try the preferred medication before using a non-preferred medication.
- Prospective Drug Utilization Review (ProDUR) Activities – ProDUR activities are automated, structured, ongoing review of prescribing, dispensing and use of medications.

**Table 5**

<b>Measures to Control Costs during CY 2023</b>		
<b>Utilization Management</b>	<b>Prior Authorization</b>	Yes
	<b>Step Therapy</b>	No
	<b>Quantity Limits</b>	Yes
<b>Pharmacy Networks</b>		No
<b>Preferred Drug List</b>		Yes
<b>ProDUR Activities</b>		Yes